BEFORE THE LEGISLATIVE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: AUGUST 6, 2009

1 P.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 85165

	INDEX	
ITEM	DESCRIPTION	PAGE NO.
1. CA	ALL TO ORDER	3
2. RO	DLL CALL	3
HOOVER C BUT NOT ON JULY	DERATION OF RESPONSE TO LITTLE COMMISSION REPORT ON CIRM, INCLUDI LIMITED TO ITEMS CONTINUED FROM M 16, 2009. (ITEMS # 6-15 IN MEMO RED JULY 16, 2009).	
A. MANAG	GEMENT RESPONSE DRAFT FOR DISCUSSI	ION
B. MEMO RECOMMEN	TO ART TORRES REGARDING TWO LHC	
PUBLIC H HEALTHCA	NSIDERATION OF ENDORSEMENT OF HEALTHCARE OPTION AS PART OF NATION RE LEGISLATION CURRENTLY UNDER RATION BY THE US CONGRESS.	72 DNAL
5. ADJO	DURNMENT	87

2

ı	DARRISIERS REPORTING SERVICE
1	THURSDAY, AUGUST 6, 2009
2	1:00 P.M.
3	
4	CHAIRMAN TORRES: IT SEEMS WE HAVE A
5	QUORUM. I WOULD LIKE TO PROCEED, FIRST OF ALL, WITH
6	THE CALL TO ORDER OF THE SUBCOMMITTEE ON
7	LEGISLATION. MELISSA, WOULD YOU PLEASE CALL THE
8	ROLL?
9	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
10	MICHAEL GOLDBERG I WILL CIRCLE BACK TO. BOB KLEIN.
11	MR. KLEIN: HERE.
12	MS. KING: CLAIRE POMEROY.
13	DR. POMEROY: HERE.
14	MS. KING: FRANCISCO PRIETO. JOHN REED.
15	DUANE ROTH.
16	MR. ROTH: HERE.
17	MS. KING: JOAN SAMUELSON.
18	MS. SAMUELSON: HERE.
19	MS. KING: JEFF SHEEHY. AND ART TORRES.
20	CHAIRMAN TORRES: HERE.
21	MS. KING: AS SOON AS MR. GOLDBERG JOINS
22	US, WE WILL HAVE A QUORUM.
23	CHAIRMAN TORRES: A QUORUM OF THIS
24	COMMITTEE IS SIX.
25	MS. KING: SEVEN.
	3

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. POMEROY: WE NEED DR. PRIETO AS WELL.
2	MR. ROTH: AND MICHAEL GOLDBERG.
3	CHAIRMAN TORRES: THAT WILL BRING US TO
4	SIX.
5	MR. KLEIN: ART, AT THE END OF THE CALL,
6	IF I COULD JUST GET FIVE MINUTES OF YOUR TIME.
7	CHAIRMAN TORRES: YES, OF COURSE.
8	MS. KING: DR. POMEROY, YOU SAID YOU HEARD
9	FROM DR. PRIETO THAT HE WAS ON HIS WAY, RIGHT?
10	DR. POMEROY: HE CALLED EARLIER CONFIRMING
11	THE ROOM LOCATION AND SAID HE WOULD BE HERE, BUT I
12	DON'T KNOW THE EXACT TIMING.
13	MR. GOLDBERG: MICHAEL GOLDBERG IS ON.
14	CHAIRMAN TORRES: WELCOME, MICHAEL. I
15	THINK WE'RE GOING TO START JUST FOR THE PURPOSES OF
16	MOVING AHEAD. I WANT TO MAKE THIS AS QUICK AS
17	POSSIBLE BECAUSE I KNOW WHAT'S AHEAD AT 4 O'CLOCK AS
18	WELL IN TERMS OF THE ICOC MEETING.
19	THE PURPOSE OF THESE TWO LEGISLATIVE
20	COMMITTEE MEETINGS WAS TO REVIEW THE RECOMMENDATIONS
21	OF THE LITTLE HOOVER COMMISSION THAT WERE PRESENTED
22	TO THE MEMBERS OF THE LEGISLATURE A FEW MONTHS AGO.
23	AS WE UNDERSTAND IT NOW, THE PURVIEW OF THE REPORT
24	IS WITHIN THE LEGISLATURE, AND SO WE ARE RESPONDING
25	TO THESE RECOMMENDATIONS AND WILL RESPOND IN WRITING
	4
	'

1	TO MEMBERS OF THE LEGISLATURE WITH RESPECT TO OUR
2	POSITION ON THESE RECOMMENDATIONS.
3	AT OUR LAST MEETING CHAIRMAN KLEIN MOVED
4	AND I SECONDED A MOTION TO REJECT THE
5	RECOMMENDATIONS ON THE GROUNDS THAT THEY WOULD
6	REQUIRE A NEW BALLOT MEASURE. AND, MOREOVER, MR.
7	KLEIN ARGUED THERE WERE SUBSTANTIVE REASONS. THE
8	MOTION WAS AMENDED BY DR. CLAIRE POMEROY TO SUGGEST
9	THAT THE MOTIVATION BEHIND REJECTING THESE
10	RECOMMENDATIONS WAS PREDICATED ON THE
11	UNCONSTITUTIONAL NATURE OF THE RECOMMENDATIONS AND
12	NOT NECESSARILY THE SUBSTANCE OF THEM. CHAIRMAN
13	KLEIN ACCEPTED THAT AMENDMENT AND THE MOTION WAS
14	PASSED EIGHT TO ZERO WITH ONE ABSTENTION, MR.
15	SHEEHY.
16	SO THAT'S WHAT WE HAVE DONE SO FAR. NOW
17	WE MOVE INTO THE SECOND AND THIRD CATEGORIES OF
18	RECOMMENDATIONS WHICH THE LITTLE HOOVER COMMISSION
19	PRESENTED TO THE LEGISLATURE. THE FIRST IS
20	REGARDING POLICY CHANGES THAT WE AS AN INSTITUTION
21	COULD IMPLEMENT. AND WE COME TO ITEM NO. 6, WHICH
22	IS MODIFY THE PREAPPLICATION REVIEW PROCESS. AND I
23	WOULD LIKE TO CALL ON OUR PRESIDENT, DR. ALAN
24	TROUNSON, TO RESPOND.
25	DR. TROUNSON: THANK YOU VERY MUCH, ART.

5

1	THE ICOC HAD AGREED TO A TRIAL PERIOD FOR THE
2	PREAPPLICATION PROCESS OF THE THREE RFA'S. THESE
3	WERE THE BASIC BIOLOGY I, BASIC BIOLOGY II, AND
4	DISEASE TEAM RESEARCH AWARDS. SO THIS TRIAL PERIOD
5	IS STILL IN PROGRESS, AND THE INFORMATION COLLECTED
6	IS AT PRESENT INCOMPLETE AS TO THE ANALYSIS AND
7	EVALUATION. WE WILL COMPLETE THIS EXPERIMENT, HAVE
8	IT ANALYZED AND EVALUATED, AND PRESENT THAT TO THE
9	ICOC IN DECEMBER THIS YEAR. AND WE EXPECT TO
10	PROVIDE SOME RECOMMENDED MODIFICATIONS AT THAT TIME.
11	CHAIRMAN TORRES: ANY COMMENT FROM ANY
12	MEMBER OF THE COMMITTEE?
13	MS. SAMUELSON: ART, I NEED A LITTLE JUST
14	DIRECTION TO BE SURE OF WHAT IT IS I SHOULD BE
15	LOOKING AT AND THE COMBINATION OF WHICH IS WHAT'S
16	BEFORE US. I'M LOOKING AT THE DRAFT FOR DISCUSSION.
17	CHAIRMAN TORRES: YES.
18	MS. SAMUELSON: AND THEN I TAKE IT THERE'S
19	ONE OTHER ITEM ASIDE FROM THIS, ONE OTHER DOCUMENT
20	ASIDE FROM THIS.
21	MS. KING: YES. THAT WOULD BE LABELED
22	AGENDA ITEM NO. 3, AND IT'S A MEMO. SO IT SAYS
23	MEMORANDUM AT THE TOP. IT'S THE MEMO FROM ROBERT
24	KLEIN AND ART TORRES TO THE GOVERNING BOARD.
25	MS. SAMUELSON: RE LITTLE HOOVER
	6
	ı

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	COMMISSION REPORT ON CIRM.
2	MS. KING: THAT IS THE DOCUMENT THAT WILL
3	BE REFERRED TO THROUGHOUT THE CALL WHEN WE'RE
4	TALKING ABOUT PARTICULAR NUMBERS THAT WE'RE
5	RESPONDING TO. THIS IS NO. 6. NO. 7 IS THE NEXT
6	ONE. IT IS THIS DOCUMENT THAT IS THE MASTER
7	DOCUMENT.
8	CHAIRMAN TORRES: NOW, YOU HAVE THE DRAFT
9	FOR DISCUSSION WHICH CITES DR. TROUNSON'S RESPONSE
10	TO ITEM NO. 6, RIGHT, 6 THROUGH 13? IT'S A
11	ONE-PAGER.
12	MS. SAMUELSON: YES. AND I ALSO HAVE A
13	MEMORANDUM DATED JUNE 30.
14	MS. KING: THAT'S THE MASTER DOCUMENT IN
15	TERMS OF THE NUMBERS THAT WE'RE REFERRING TO.
16	CHAIRMAN TORRES: AND THE CATEGORIES BY
17	WHICH WE ARE REVIEWING THEM, JOAN.
18	ARE THERE ANY OTHER RESPONSES FROM MEMBERS
19	OF THE COMMITTEE ON DR. TROUNSON'S RESPONSE TO ITEM
20	NO. 6? IT'S PRETTY PERFUNCTORY.
21	DR. POMEROY: FIRST OFF, ALTHOUGH FROM
22	SACRAMENTO.
23	DR. PRIETO: FRANCISCO PRIETO. I'VE
24	JOINED THE MEETING.
25	MS. KING: DID ANYBODY ELSE JOIN?
	7
	<i>'</i>

1	DR. LEVIN: YES. JACOB LEVIN FROM UC
2	IRVINE AND A MEMBER OF THE PUBLIC.
3	DR. POMEROY: WE ALSO HAVE ONE ADDITIONAL
4	MEMBER OF THE PUBLIC.
5	MR. ENGELHARDT: RITCHARD ENGELHARDT,
6	CALIFORNIA HEALTHCARE INSTITUTE.
7	CHAIRMAN TORRES: THANK YOU FOR BEING
8	HERE.
9	DR. POMEROY: ON THIS ONE CAN WE JUST
10	BRIEFLY GET A SUMMARY OF WHAT THE LITTLE HOOVER
11	COMMISSION RECOMMENDED FOR MODIFICATIONS AND WHAT
12	THE EXPERIMENT INCLUDES?
13	DR. TROUNSON: THE EXPERIMENT WAS REQUIRED
14	BY RECOMMENDED BY THE BOARD WHEN WE PUT THE
15	PREAPPLICATION REVIEW PROCESS FORWARD, THAT IT WOULD
16	BE AN EXPERIMENTAL PERIOD FOR WHICH WE WOULD REPORT
17	BACK TO THE BOARD AND AN EVALUATION OF HOW IT
18	PROGRESSED. SO WE ARE IN THAT TRIAL PROCESS,
19	EXPERIMENTAL PROCESS.
20	DR. POMEROY: I UNDERSTAND THAT. WHAT I'M
21	TRYING TO GET IS A LIST OF THE INTERVENTIONS THAT
22	WERE INVOLVED IN THE EXPERIMENT.
23	MR. KLEIN: ARE YOU SAYING YOU'RE
24	ASKING WHAT THE LITTLE HOOVER COMMISSION
25	RECOMMENDED?
	8
	U

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. POMEROY: AND THEN THAT'S THE FIRST
2	QUESTION, AND THE SECOND QUESTION WAS WHAT
3	MODIFICATIONS ARE WE DOING AN EXPERIMENT ON?
4	CHAIRMAN TORRES: WHY DON'T WE PROCEED
5	WITH THE LITTLE HOOVER COMMISSION TELLING US WHAT
6	THEY RECOMMENDED SINCE THEY'RE THERE?
7	DR. POMEROY: I JUST FEEL LIKE WE'RE
8	DISCUSSING RECOMMENDATIONS AND WE HAVEN'T SAID WHAT
9	THE RECOMMENDATION WAS, AND THEN WE'VE SORT OF
10	DISMISSED IT AS, WELL, WE'RE TRYING AN EXPERIMENT
11	AND WE HAVEN'T SAID WHAT THE EXPREIMENT IS. SO I'M
12	JUST TRYING TO GET THAT ON THE RECORD.
13	MR. KLEIN: AS AN INFORMATIONAL ITEM, IT'S
14	IMPORTANT TO NOTE THAT THE LITTLE HOOVER COMMISSION
15	IN THEIR REPORT INITIALLY BELIEVED THAT, IN FACT,
16	THIS PROCESS OF PREAPPLICATION REVIEW RELIED
17	COMPLETELY ON INTERNAL STAFF, WHICH WAS NOT CORRECT.
18	THERE ARE THREE OUTSIDE SPECIALISTS THAT WE UTILIZED
19	TO LOOK AT EACH GROUP OF APPLICATIONS, AND THEN
20	THOSE EVALUATIONS WERE BROUGHT IN-HOUSE WHERE THEN
21	THE STAFF LOOKED AT THE CRITERIA TO SEE IF THE
22	APPLICATIONS WERE RESPONSIVE TO THE RFA CRITERIA.
23	THE IN-HOUSE STAFF DID NOT DO A REVIEW. IN-HOUSE
24	STAFF, IN FACT, WAS LOOKING FOR RESPONSIVENESS TO
25	SPECIFIC CRITERIA AND INCORPORATING THE INFORMATION
	α

1	FROM THE OUTSIDE SPECIALISTS IN DETERMINING WHICH
2	APPLICATIONS WOULD BE DEFERRED AND WHICH WOULD BE
3	RECOMMENDED TO GO FORWARD AT THIS TIME.
4	DR. TROUNSON, THAT'S A SUMMARY. IS THAT
5	SUMMARY, YOU FEEL, ACCURATE?
6	DR. TROUNSON: WELL, ESSENTIALLY IT WAS A
7	TRIAL PERIOD THAT I'VE DESCRIBED AS AN EXPERIMENT, A
8	TRIAL PERIOD FOR WHICH WE WOULD REPORT BACK TO THE
9	BOARD ON HOW IT WORKED. AND YOU'VE BASICALLY
10	DESCRIBED THE PROCESS AS IT IS. WE HAVE TAKEN
11	SURVEYS FROM THE APPLICANTS OF EACH OF THE RFA'S,
12	AND WE WILL BE REPORTING THOSE SUMMARIES TO THE
13	BOARD IN DECEMBER.
14	THE SUBSTANCE OF THE LITTLE HOOVER
15	COMMISSION WAS TO MAKE A RECOMMENDATION TO MODIFY
16	THE PREAPPLICATION REVIEW PROCESS WITHOUT BEING
17	SPECIFIC TO WHAT THE MODIFICATION SHOULD BE. BUT
18	
	ESSENTIALLY WE WILL BE BRINGING FORWARD PROBABLY A
19	RECOMMENDATION TO MODIFY THE PROCESS AT THE
19 20 21	RECOMMENDATION TO MODIFY THE PROCESS AT THE
20	RECOMMENDATION TO MODIFY THE PROCESS AT THE COMPLETION OF THE TRIAL PERIOD.
20 21	RECOMMENDATION TO MODIFY THE PROCESS AT THE COMPLETION OF THE TRIAL PERIOD. SO WHAT I'M BASICALLY SAYING IS THE
20 21 22	RECOMMENDATION TO MODIFY THE PROCESS AT THE COMPLETION OF THE TRIAL PERIOD. SO WHAT I'M BASICALLY SAYING IS THE PROCESS IS UNDER WAY FOR EVALUATION, AND WE WILL
20212223	RECOMMENDATION TO MODIFY THE PROCESS AT THE COMPLETION OF THE TRIAL PERIOD. SO WHAT I'M BASICALLY SAYING IS THE PROCESS IS UNDER WAY FOR EVALUATION, AND WE WILL REPORT IT TO THE BOARD, WHICH WILL PROBABLY INCLUDE

INDULGE ME, I WOULD LIKE TO CALL ON JAMES HARRISON
TO GIVE US THE RECOMMENDATION VERBATIM FROM THE
LITTLE HOOVER REPORT, AND THAT WAY WE HAVE IT ON THE
RECORD.
DR. POMEROY: THANK YOU.
MR. HARRISON: THE LITTLE HOOVER
COMMISSION DID ADDRESS WHAT THEY REFERRED TO AS THE
TRIAGE PROCESS, WHAT WE CALL THE PREAPPLICATION
PROCESS. IN THEIR REPORT THEY STATED THAT THEY
BELIEVED THAT IT DEVIATED FROM BEST PRACTICES AND
ADDED A LAYER OF OPACITY TO CIRM'S PROCESSES. AND
THEIR RECOMMENDATION STATES SIMPLY, "CIRM SHOULD
MODIFY ITS TRIAGE PLAN TO REVIEW GRANTS INTERNALLY."
SO THEY DID NOT OFFER ANY SPECIFICS AS TO HOW IT
SHOULD BE MODIFIED.
CHAIRMAN TORRES: OUR RESPONSE IS THAT WE
WILL PROVIDE MODIFICATIONS AFTER WE'VE REVIEWED IT
AND PRESENTED IT IN DECEMBER OF THIS YEAR, 2009.
ARE THERE ANY OTHER COMMENTS FROM
COMMITTEE MEMBERS ON THIS PARTICULAR ISSUE? ARE
THERE PUBLIC COMMENTS IN SACRAMENTO?
MR. JENSON: DAVID JENSON WITH CALIFORNIA
STEM CELL REPORT. A QUESTION HERE. WAS THERE ANY
DIFFERENCE IN THE TRIAGE THAT WAS PERFORMED ON THE
DISEASE TEAM GRANTS AND THE STEM CELL BIOLOGY?
11

1	DR. TROUNSON: THERE WAS NO DIFFERENCE
2	ESSENTIALLY BETWEEN THOSE PROCESSES.
3	MR. JENSON: OKAY.
4	CHAIRMAN TORRES: ANY OTHER PUBLIC
5	COMMENTS IN SACRAMENTO? LET'S MOVE TO SAN DIEGO.
6	ANY PUBLIC COMMENTS THERE?
7	MR. ROTH: NO.
8	CHAIRMAN TORRES: IRVINE?
9	DR. LEVIN: NO.
10	CHAIRMAN TORRES: KFC?
11	MR. KLEIN: NO.
12	CHAIRMAN TORRES: MOUNTAIN VIEW?
13	MR. GOLDBERG: NO.
14	CHAIRMAN TORRES: HEALDSBURG?
15	MS. SAMUELSON: IT'S JOAN. JUST SO I
16	UNDERSTAND. SO THE LITTLE HOOVER COMMISSION DID NOT
17	MAKE A RECOMMENDATION OF A SPECIFIC PROCEDURAL
18	CHANGE?
19	CHAIRMAN TORRES: CORRECT.
20	MS. SAMUELSON: BUT THEY THOUGHT THE
21	PROCESS SHOULD BE LOOKED AT SOMEHOW?
22	CHAIRMAN TORRES: WHICH WE HAVE AGREED TO
23	DO.
24	MS. SAMUELSON: GOOD. GOT IT.
25	CHAIRMAN TORRES: SAN FRANCISCO, ANY
	12

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PUBLIC COMMENT?
2	LET'S MOVE ON ITEM NO. 7, IDENTIFY ALL OF
3	THE APPLICANTS IN CONNECTION WITH AN RFA ON TRIAL
4	BASIS. CAN WE HEAR WHAT THE LITTLE HOOVER
5	COMMISSION RECOMMENDED, AND THEN OUR PRESIDENT WILL
6	RESPOND.
7	MR. HARRISON: THE LITTLE HOOVER
8	COMMISSION RECOMMENDATION RECOMMENDED, RATHER, THAT
9	CIRM SHOULD CONDUCT A TRIAL GRANT APPLICATION ROUND
10	THAT IDENTIFIES ALL APPLICANTS. AND THEY POINTED TO
11	CONNECTICUT AS A MODEL THAT CIRM MIGHT CONSIDER
12	FOLLOWING.
13	CHAIRMAN TORRES: ALL RIGHT. DR.
14	TROUNSON.
15	DR. TROUNSON: SO WE BELIEVE VERY STRONGLY
16	IN MANAGEMENT THIS IS INAPPROPRIATE BECAUSE THERE'S
17	NO GRANTING AGENCIES THAT WE'RE AWARE OF THAT FOLLOW
18	THIS PROCEDURE OTHER THAN CONNECTICUT. AND IT'S OUR
19	VIEW THAT IT'S NOT CONSIDERED BEST PRACTICE, NOR IS
20	IT COMMONLY USED. THERE IS A RECENT DOCUMENT FROM
21	THE NIH, IF YOU CARE TO READ THAT, ON THESE MATTERS
22	OF CONFIDENTIALITY, AND THERE IS NO SUCH
23	RECOMMENDATION THERE EITHER.
24	CONFIDENTIALITY IS CRUCIAL TO ENSURING THE
25	INTEGRITY OF THE REVIEW PROCESS. NAMES OF

13

1	SUBMITTING INSTITUTIONS AND INDIVIDUALS AS WELL AS
2	THE APPLICATION CONTENT AND PEER EVALUATIONS ARE
3	KEPT CONFIDENTIAL EXCEPT TO THOSE INVOLVED IN THE
4	REVIEW PROCESS TO THE EXTENT PERMITTED BY LAW.
5	DISCLOSURE OF SCIENTIST'S FAILURES IN
6	GRANT COMPETITION WOULD HAVE A NEGATIVE IMPACT ON
7	THEIR CAREERS AND MAKE THEM RELUCTANT TO PROPOSE
8	HIGHLY INNOVATIVE PROJECTS THAT OFTEN MOVE SCIENCE
9	FORWARD.
10	CIRM PLANS TO EXPAND ITS PARTNERSHIPS WITH
11	INDUSTRY, AND IT WILL BE COMPROMISED BY DISCLOSURE
12	OF UNSUCCESSFUL APPLICATIONS THAT COULD THWART A
13	COMPANY'S ABILITY TO RAISE FUNDS.
14	I'D ALSO JUST POINT OUT, MR. CHAIRMAN,
15	THAT YOU'RE NOT REQUIRED TO OR EXPECTED, NOR IS IT
16	NORMAL THAT YOU PUT ON YOUR CURRICULUM VITAE
17	PROJECTS WHICH ARE UNSUCCESSFUL, NOR DO I KNOW ANY
18	GRANT APPLICATION PROCESS THAT REQUIRES YOU TO
19	IDENTIFY APPLICATIONS TO ANY GRANT BODIES THAT WERE
20	UNSUCCESSFUL.
21	SO MY OWN VIEW AND THOSE OF MANAGEMENT IS
22	THAT THIS IS NOT A PRACTICE AND, IN FACT, IT WOULD
23	BE DETRIMENTAL TO OUR ABILITY TO MOVE.
24	CHAIRMAN TORRES: THANK YOU, MR.
25	PRESIDENT. COMMENTS FROM MEMBERS OF THE COMMITTEE?
	1.4

1	MS. SAMUELSON: THIS IS ONE WHERE I'M
2	INCLINED TO WANT TO PROBE A LITTLE FURTHER.
3	CHAIRMAN TORRES: PLEASE.
4	MS. SAMUELSON: I THINK MORE TRANSPARENCY
5	ABOUT THE APPLICANTS, ASSUMING IT DOESN'T HAVE SOME
6	KIND OF REALLY SIGNIFICANT DETRIMENTAL EFFECT ON
7	CAREERS OR ON THE PROCESS OF DEVELOPMENT OF
8	INNOVATIVE RESEARCH, COULD BE A GOOD THING. AND THE
9	FACT THAT SOME OF THESE OTHER RESEARCH ENTERPRISES,
10	LIKE THE NIH, DON'T DO IT ISN'T COMPELLING TO ME
11	BECAUSE I SEE WHAT WE'RE DOING AS HIGHLY INNOVATIVE
12	IN COMPARISON AND URGENT. AND THAT IT'S REALLY
13	THERE ARE ENOUGH DIFFERENCES THAT I WOULDN'T ASSUME
14	THAT THAT WOULD BE A SOLID PRECEDENT.
15	MR. KLEIN: JOAN, THIS IS BOB. I KNOW HOW
16	IMPORTANT YOU THINK IT IS TO HAVE THE PRIVATE SECTOR
17	INVOLVED. AND I'D LIKE TO GET SOME MORE DEPTH ON A
18	VERY VALID POINT THAT WAS MADE BY ALAN, WHICH IS IF
19	YOU'RE NEGOTIATING AS A PRIVATE COMPANY TO GET A
20	CRITICAL ROUND OF VENTURE CAPITAL FUNDING AND YOU'RE
21	ADVOCATING THE IMPORTANCE OF A SPECIFIC MEDICAL
22	ADVANCE THAT IS IN YOUR PORTFOLIO, I WONDER IF DUANE
23	COULD COMMENT ON WHAT WOULD HAPPEN POTENTIALLY TO
24	THAT SENSITIVE NEGOTIATION IF THERE WERE A PUBLIC
25	DENIAL OF A GRANT FOR THAT AS NOT RECOMMENDED FOR
	15

1	FUNDING AT THE TIME THAT NEGOTIATION IS GOING ON.
2	MR. ROTH: I'D BE HAPPY TO COMMENT. LET
3	ME JUST MAKE A GENERAL COMMENT, JOAN, TO START OFF.
4	AS GOOD AS OUR REVIEW PROCESS IS AND AS MUCH
5	INTEGRITY AS I THINK IS IN IT, IT'S NOT PERFECT.
6	AND I THINK ANY OTHER REVIEW ORGANIZATION OR GRANT
7	ORGANIZATION WOULD TELL YOU THAT THEY OFTEN MISSED
8	SOME OF THE MORE INNOVATIVE THINGS BECAUSE THEY
9	DIDN'T FULLY APPRECIATE OR UNDERSTAND OR A
10	PARTICULAR REVIEWER JUST FELT IT WAS TOO FAR OUT FOR
11	ALL OF THOSE REASONS.
12	BUT I THINK IN THIS PARTICULAR CASE, FROM
13	AN INDUSTRY PERSPECTIVE, THEY COULD WELL SCORE VERY
14	LOW. IN FACT, AS YOU KNOW, WE'VE NOT AWARDED A LOT
15	OF INDUSTRY GRANTS. WE'RE CONCERNED ABOUT THE WAY
16	THEY WRITE THE GRANTS, AND PERHAPS THAT'S PART OF
17	THE CHALLENGE. BUT TO DISCLOSE SCORES THAT WOULD
18	CAUSE THEM THEY WOULD BE LOW, THEY WOULD BE
19	UNFUNDED, AND IT CAUSED THEM TO HAVE TO EXPLAIN WHY
20	THE REVIEWERS DIDN'T FULLY APPRECIATE WHAT IT IS
21	THEY WERE DOING, I THINK, WOULD CREATE A NEGATIVE
22	RELATIONSHIP BETWEEN US AND THE INDUSTRY. IF THEY
23	CHOOSE TO DISCLOSE IT, THAT'S THEIR BUSINESS.
24	MS. SAMUELSON: I HEAR YOU.
25	MR. ROTH: BUT I THINK WE HAVE TO BE VERY

16

1	CAREFUL HERE ON THE INDUSTRY SIDE, PARTICULARLY
2	THOSE SMALL COMPANIES THAT ARE ALREADY PUBLIC,
3	BECAUSE THEY WOULD HAVE TO PUT THAT POTENTIALLY INTO
4	A RESPONSE IN A PRESS RELEASE. SO I WOULD LIKE TO
5	AVOID THAT.
6	MS. SAMUELSON: BUT I WOULDN'T THINK THAT
7	IF THEY HAVE THAT DISCLOSURE OBLIGATION, THAT THE
8	FACT THAT IT WASN'T DISCLOSED BY CIRM THAT THEY WERE
9	AN APPLICANT WOULD RELIEVE THEM OF THAT DISCLOSURE,
10	FOR ONE THING. AND I ALSO THINK THAT THE MORE
11	IMPORTANT POINT IS I THINK IT'S AWFULLY IMPORTANT
12	THAT WE GET RIGHT OUR PROCESS OF REVIEW SO THAT IT
13	DOESN'T GIVES DUE CREDIT TO PROJECTS THAT ARE
14	INNOVATIVE AND THEREFORE RISKY AND LACKING
15	VOLUMINOUS DATA AND SO ON. WE NEED TO GET THAT
16	RIGHT, AND I'M NOT SURE THAT TRANSPARENCY THERE
17	WOULDN'T MAYBE HELP US FOCUS ON IT. AND WE DON'T
18	WANT ANY UNWITTING VICTIMS OF THAT. I COMPLETELY
19	GET THAT.
20	MR. ROTH: I DON'T KNOW HOW DISCLOSURE OF
21	WHO THE GRANT APPLICANTS THAT WERE UNSUCCESSFUL
22	HELPS US ADDRESS THAT ISSUE. WE SHOULD REACH OUT TO
23	THEM, AND I THINK WE ARE MAKING AN ATTEMPT TO DO
24	THAT, BUT I DON'T THINK MAKING IT PUBLIC ADDS
25	ANYTHING TO THAT.
	17
	17

1	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER
2	COMMENTS FROM MEMBERS OF THE COMMITTEE? WE'LL GO TO
3	PUBLIC COMMENTS. SACRAMENTO?
4	MR. DROWN: THIS IS STUART DROWN. WE
5	LOOKED AT THIS NOT AS CIRM BEING AN INVESTMENT
6	BANKER OR VENTURE CAPITALIST. WE LOOKED AT THIS AS
7	CIRM BEING A PUBLIC AGENCY AND PEOPLE APPLYING FOR
8	GRANTS FROM A PUBLIC AGENCY. WE'RE ASKING FOR THE
9	IDENTITIES OF THE APPLICANTS, NOT THE SCORES. AND
10	THE IDENTITIES ARE TRYING TO SHIFT FROM AN INSIDE
11	VIEW TO AN OUTSIDE VIEW, THE WAY THAT THE ICOC SEES
12	ITS SCORING PROCESS AND THE RESULTS NATURALLY IS
13	INVESTED IN THE WAY YOU PUT TOGETHER THAT PROCESS.
14	BUT I THINK IT'S IMPORTANT TO INCREASE TRANSPARENCY
15	AND ACCOUNTABILITY FOR THE PUBLIC'S SAKE FOR THEM TO
16	BE ABLE TO SEE WHO THE APPLICANTS ARE AND HAVE AN
17	OUTSIDE OPPORTUNITY TO DISCERN WHETHER THERE IS A
18	TREND OR A BIAS, TO SEE WHETHER GRANTS ARE GOING ALL
19	IN ONE DIRECTION OR ALL IN ANOTHER, AND TO ALLOW
20	BOTH THE APPLICANT POOL OR THE POTENTIAL APPLICANT
21	POOL AS WELL AS THE GENERAL PUBLIC TO BE IN A
22	POSITION TO FAIRLY COMMENT ON THAT AS CIRM AS A
23	PUBLIC AGENCY.
24	THIS WOULD NOT PRECLUDE CIRM FROM WORKING
25	WITH THOSE APPLICANTS TO IMPROVE THEIR APPLICATIONS
	18

1	FOR LATER, AND IT WOULD NOT NECESSARILY DOESN'T
2	HAVE TO REFLECT BADLY DEPENDING ON HOW THEY DO IT.
3	THE THIRD THING IS I'M NOT SURE WHETHER
4	DAVID HAD A THOUGHT ABOUT SEC. IN ANY EVENT, THIS
5	IS DESIGNED AS A WAY TO BUILD CONFIDENCE IN YOUR
6	PROCESS TO GET BEYOND THE FACT THAT MANY OF THESE
7	APPLICANTS MAY BE IT WOULD TAKE AWAY ONE OF THE
8	LAYERS OF OPACITY.
9	CHAIRMAN TORRES: WHERE HAS THE LACK OF
10	CONFIDENCE BEEN DOCUMENTED?
11	MR. DROWN: I'M NOT ADDRESSING THAT. ALL
12	I'M ASKING WE'RE RECOMMENDING A WAY TO GIVE THE
13	PUBLIC A WAY TO JUDGE INDEPENDENTLY THIS PROCESS.
14	MR. KLEIN: ART.
15	CHAIRMAN TORRES: FIRST MR. SHEEHY HERE IN
16	SAN FRANCISCO AND THEN MR. KLEIN.
17	MR. SHEEHY: WITH RESPECT TO MR. DROWN, I
18	APPRECIATE ALL THE HARD WORK THEY'VE DONE. JUST
19	RIGHT OFF THE BAT, I DON'T THINK THAT ANY TYPE OF
20	ANALYSIS HAS BEEN DONE IN ORDER TO PREPARE US TO
21	RADICALLY CHANGE HOW PEER REVIEW IS DONE IN THIS
22	COUNTRY. WE'RE TALKING ABOUT A PROCESS THAT'S VERY
23	WELL RECEIVED, THAT IS THE GOLD STANDARD FOR
24	REVIEWING SCIENCE GLOBALLY, HOW THE NIH DOES IT, AND
25	THE CONFIDENTIALITY OF THE PEER REVIEW PROCESS.
	10

1	IF WE WERE GOING TO START TO ATTACK THAT
2	ISSUE, I THINK WE WOULD NEED A MUCH MORE EXHAUSTIVE
3	ANALYSIS OF WHAT THE IMPLICATIONS WOULD BE. WE
4	CAN'T JUST WILLY-NILLY SAY THAT WE WANT TO DO THIS
5	WHEN THIS IS HOW SCIENCE IS REVIEWED IN THIS
6	COUNTRY, AND IT'S THE STANDARD FOR SCIENTISTS AND
7	IT'S HOW PEOPLE EXPECT IT TO PROCEED.
8	MY SECOND POINT IS THAT THE REAL THOSE
9	WHO HAVE AN OBJECTION TO WHAT THE REVIEW PROCESS HAS
10	BEEN, WE PUT IN PLACE A PROCESS WHERE THEY CAN COME
11	TO THE BOARD, THEY CAN MAKE PUBLIC COMMENT, THEY CAN
12	WRITE FAIRLY WELL DOCUMENTED YOU KNOW, WE GIVE
13	THEM SPACE TO DELIVER A MESSAGE TO STAFF AND HAVE AN
14	ANALYSIS OF WHAT THE REVIEW WAS DONE.
15	SO I THINK THE SAFEGUARD FOR THE PUBLIC IS
16	ACTUALLY FOUND IN THE ACTIONS OF THE INDIVIDUAL
17	GRANT APPLICANTS AND HOW THEY RESPOND TO THEIR
18	SCORES TO THE REVIEWS. THEY ARE ABLE TO AFFORD
19	THEMSELVES OF ALL THE PROCESSES THAT A PUBLIC AGENCY
20	AFFORDS. THEY CAN COME TO APPEAL TO US.
21	WE HAVE PUT IN A VERY RIGOROUS REVIEW
22	PROCESS FOR THIS AND IT'S ALL VERY PUBLIC. BUT WE
23	ALSO HAVE TO RESPECT THE CONFIDENTIALITY AND THE
24	NECESSARY INTELLECTUAL PROPERTY THAT IS DISCLOSED IN
25	A GRANT APPLICATION BY THE APPLICANT. AND SO ANY

INDIVIDUAL APPLICANT CAN BE AS PUBLIC AS THEY WANT
AT ANY POINT AND DISCLOSE AS MUCH AS THEY WANT TO
DISCLOSE IN THE PUBLIC COMMENT PERIOD AT AN ICOC
MEETING, AND THEY DO SO.
THOSE WHO ARE NOT WILLING OR INTERESTED IN
DOING SO I TEND TO THINK AGREE WITH THE REVIEWS THEY
GOT AND ARE HAPPY WITH THE PROCESS AND COME BACK
NEXT TIME AND TRY AGAIN. SO I DON'T THINK THAT THIS
REALLY DOES BENEFIT PUBLIC UNDERSTANDING FOR US TO
DISCLOSE INFORMATION THAT TAKES US RADICALLY OUTSIDE
THE REALM OF HOW SCIENCE IS TYPICALLY REVIEWED IN
THIS COUNTRY.
CHAIRMAN TORRES: THANK YOU, MR. SHEEHY.
MR. KLEIN.
MR. KLEIN: I'D LIKE TO ECHO JEFF'S
COMMENTS, THAT I THINK THAT THE APPLICANT IS IN THE
BEST POSITION TO JUDGE WHETHER THEY THINK THEY'VE
BEEN TREATED FAIRLY OR WHETHER CERTAIN ITEMS HAVE
BEEN OVERLOOKED. BY HAVING A PUBLIC FORUM FOR BOTH
WRITTEN COMMENTS THAT GO DIRECTLY TO THE BOARD AND
PUBLIC DISCUSSION WITH THE BOARD ON ANY ISSUE OF
FAIRNESS OR APPRECIATION OF THE SCIENCE, WHICH IS
REALLY MORE THE FOCUS OF EVERYTHING THAT WE RECEIVED
THUS FAR, I THINK THAT THE APPLICANTS THEMSELVES, AS
JEFF SAID, ACT AS THE SURROGATES FOR THE PUBLIC TO
21

1	BRING TO OUR ATTENTION ANYTHING WHERE THEY THINK
2	THAT THE REVIEW HASN'T BEEN THOROUGH.
3	AND THERE HAVE BEEN OCCASIONS WHERE THE
4	BOARD, IN FACT, HAS LISTENED TO THE PUBLIC FORUM
5	PRESENTATIONS AND TAKEN ACTIONS THAT WERE DIFFERENT
6	THAN THE PEER REVIEW GROUP'S RECOMMENDATION AND/OR
7	STAFF RECOMMENDATION. SO WE DO HAVE A FAIL-SAFE
8	SYSTEM TO PROTECT THE PUBLIC AND THE SCIENCE AND
9	BRING TO THE BOARD'S ATTENTION AND THE PUBLIC'S
10	ATTENTION ANYTHING WHERE THERE IS A QUESTION.
11	THE OTHER ISSUE THAT I STILL BELIEVE IS
12	UNESTIMATED IS, JOAN, WHILE THE INDIVIDUAL COMPANY
13	MAY APPLY A NUMBER OF PLACES FOR GRANTS, INCLUDING
14	DISEASE ORGANIZATIONS, THEY DON'T HAVE AN
15	OBLIGATION, PARTICULARLY IF THEY FEEL THAT THE
16	EVALUATION DIDN'T UNDERSTAND THE MATURITY OF THEIR
17	SCIENCE OR HOW THEY WERE GOING TO OVERCOME CERTAIN
18	OBSTACLES, THEY DON'T HAVE AN OBLIGATION, IF THEY
19	CAN ANSWER THOSE QUESTIONS, TO DO A DISCLOSURE ON
20	IT. BUT IF YOU PUT IT INTO THE PUBLIC WHEN THEY'RE
21	TRYING TO DO AN IPO, INITIAL PUBLIC OFFERING, OR
22	WHEN THEY'RE PUBLICLY TRADED OR WHEN THEY'RE IN A
23	SENSITIVE VENTURE CAPITAL ROUND, YOU'VE NOW MADE IT
24	FRONT AND CENTER AN ISSUE THEY'RE GOING TO HAVE TO
25	EXPLAIN WHY OUR PEER REVIEW WAS WRONG, WHY OUR BOARD

WAS WRONG. THAT PUTS A TREMENDOUS BURDEN ON THEM IN
AN ENVIRONMENT WHERE THEY'RE LIMITED BY ANY RFA TO A
CERTAIN NUMBER OF PAGES, AND THEY MAY HAVE BEEN ABLE
TO MARSHAL MUCH MORE DATA THAN THE APPLICATION
PROCESS ALLOWED.
SO WE CAN'T BELIEVE WE'RE PERFECT. WE
HAVE TO BELIEVE THAT WE GIVE EVERYONE THE
OPPORTUNITY AND WE DON'T WANT TO NEGATIVELY IMPACT
THEIR ABILITY TO RAISE CAPITAL FROM OTHER PLACES.
AND HAVING AND NOT CREATING NEGATIVE IMPACTS ON
COMPANIES APPLYING IS VERY IMPORTANT TO US.
CHAIRMAN TORRES: ANY OTHER PUBLIC
COMMENTS IN SACRAMENTO?
MR. JENSON: DAVE JENSON, THE CALIFORNIA
STEM CELL REPORT. I JUST WANTED TO NOTE HERE THAT,
IN FACT, THE STEM CELL AGENCY HAS NOT MAINTAINED
CONFIDENTIALITY ON NAMES OF APPLICANTS IN ALL CASES,
MOST NOTABLY IN THE FACILITIES GRANTS. SO WHERE
THEY RELEASED OF THE NAMES WERE RELEASED BY THE
AGENCY ITSELF WHILE IN THE PROCESS.
ADDITIONALLY, THE GRANT SUMMARIES
OFTENTIMES, IN FACT PERHAPS MANY TIMES, CONTAIN
INFORMATION THAT IS SUFFICIENT TO IDENTIFY
APPLICANTS.
AND FINALLY, SOME OF THESE PUBLIC
23

1	COMPANIES MAY HAVE TO REPORT THE REJECTION, AN
2	APPLICATION FOR A GRANT TO THE SEC IF IT IS A
3	SIGNIFICANT FINANCIAL EVENT.
4	CHAIRMAN TORRES: THEN WE'RE ALL COVERED.
5	ALL RIGHT. ANY OTHER PUBLIC COMMENTS IN SACRAMENTO?
6	DR. PRIETO: I JUST WOULD REMIND, I THINK,
7	SOME OF THE MEMBERS RECALL THAT WE HAD DISCUSSED AT
8	ONE POINT, BUT DIDN'T TAKE ACTION, ON IDENTIFYING
9	GRANTEE INSTITUTIONS, ALTHOUGH THIS WAS IN AN
10	EARLIER STAGE IN CIRM'S HISTORY. AND AS WE GET INTO
11	FUNDING PRIVATE COMPANIES, I CAN IMAGINE THAT THE
12	IMPACT ON PEOPLE'S CAREERS, I THINK, IS A REAL
13	CONCERN, AND SOME OF THESE, IF NOT MOST OF THESE
14	COMPANIES, THERE MAY ONLY BE ONE PRINCIPAL
15	RESEARCHER AND LAB WORKING ON STEM CELL ISSUES. AND
16	SO IDENTIFYING THE INSTITUTION WOULD IDENTIFY THE
17	RESEARCHER.
18	SO WE HAVE VISITED THIS ISSUE BEFORE. AND
19	I GUESS I DON'T SEE I UNDERSTAND THE NEED FOR
20	TRANSPARENCY OR I APPRECIATE AND WOULD LIKE TO SEE
21	MORE TRANSPARENCY; BUT I THINK, AS JEFF SAID, WE
22	WOULD HAVE TO LOOK AT THIS VERY CAREFULLY TO FIGURE
23	OUT A WAY TO DO IT WITHOUT HARMING PEOPLE'S CAREERS.
24	CHAIRMAN TORRES: ANY OTHER COMMENTS FROM
25	SACRAMENTO?
	24

1	DR. POMEROY: I THOUGHT ABOUT THIS ONE A
2	LOT BECAUSE I THINK THIS IS REALLY A MATTER OF
3	BALANCING TWO GOOD INTENTIONS. AND I THINK THE
4	INTENTION OF TRANSPARENCY IS A GOOD ONE. IT'S
5	IMPORTANT FOR BUILDING TRUST. BUT I THINK WE HAVE
6	TO BALANCE THAT AGAINST THE GOOD OF ENCOURAGING AS
7	MUCH INCLUSIVENESS AS WE CAN IN APPLICANTS. AND SO
8	I THINK THAT REVEALING THE FAILURES DOES LIE OUTSIDE
9	THE EXPERIENCE OF MOST ACADEMICIANS, MOST
10	INVESTIGATORS, AND I FEAR THAT TRYING SOMETHING LIKE
11	THIS COULD DISCOURAGE THE NUMBER AND VARIETY AND
12	DIVERSITY OF PEOPLE WHO APPLIED. AND, THEREFORE, WE
13	MIGHT NOT BE GETTING ALL THE GOOD IDEAS THAT WE
14	NEED.
15	AND I THINK THE NEGATIVE IMPACT THAT THAT
16	HAS ON THE MISSION OF ADVANCING THE SCIENCE, FOR ME,
17	ENDS UP OUTWEIGHING THE OTHER CONCERN IN THIS
18	BALANCE.
19	SO I THINK IT'S AN IMPORTANT DISCUSSION TO
20	HAVE, BUT I END UP COMING OUT ON THE SIDE OF
21	CONTINUING TO TRY TO EMULATE THE NIH PERSPECTIVE SO
22	THAT WE GET AS MUCH INVOLVEMENT AS WE CAN IN OUR
23	SCIENTIFIC PROGRAMS.
24	CHAIRMAN TORRES: THANK YOU, DR. POMEROY.
25	YOU WILL PROBABLY KNOW THAT'S MY POSITION AS WELL.

25

1	ANY OTHER COMMENTS FROM SACRAMENTO? ANY COMMENTS IN
2	LA JOLLA?
3	MR. ROTH: NO.
4	CHAIRMAN TORRES: IRVINE?
5	DR. LEVIN: NO.
6	CHAIRMAN TORRES: SAN FRANCISCO?
7	MR. REED: MY FEELING IS THAT THERE'S
8	ISSUES OF PRIVACY INVOLVED. I SEE THIS LIKE A JOB
9	APPLICATION. IF I WAS TO TRY FOR A JOB AND WAS
10	REJECTED FROM IT, I REALLY WOULD NOT WANT THAT
11	PUBLICIZED. BUT IF I'M REJECTED THREE AND FOUR
12	TIMES, THEY'D SAY, "OH, THERE'S DON REED. BEEN
13	REJECTED EVERYWHERE ELSE. LOSER. FORGET HIM." SO
14	I WOULD BE INCLINED TO THINK THAT
15	CHAIRMAN TORRES: YOU'RE NOT A LOSER, DON,
16	FOR THE RECORD. ANYONE ELSE IN SAN FRANCISCO?
17	MOUNTAIN VIEW? PALO ALTO?
18	MR. KLEIN: NO.
19	CHAIRMAN TORRES: ALL RIGHT. HEALDSBURG?
20	MS. SAMUELSON: IT'S A QUESTION FOR THE
21	LITTLE HOOVER FOLKS.
22	CHAIRMAN TORRES: STUART, ARE YOU STILL
23	THERE?
24	MR. DROWN: I'M STILL HERE.
25	MS. SAMUELSON: IN MAKING THIS REQUEST IN
	26

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THIS PARTICULAR RECOMMENDATION, DID YOU HAVE ANY
2	EXPERTISE YOU WERE LOOKING TO BEYOND REGARDING US AS
3	THE CIRM AND SO AS A PUBLIC AGENCY?
4	MR. DROWN: PUBLIC AGENCY AND THE
5	EXPERIENCE OF CONNECTICUT AND THE FACT THAT, AS A
6	PUBLIC AGENCY, YOU WERE MOVING INTO A ZONE WHERE YOU
7	WOULD BE GIVING LOANS AND GRANTS TO PRIVATE
8	BUSINESSES.
9	CHAIRMAN TORRES: CONNECTICUT IS THE ONLY
10	STATE THAT HAS A PROGRAM THAT YOU FEEL WE SHOULD
11	IMPLEMENT HERE?
12	MR. DROWN: AT THIS POINT.
13	MR. ROTH: I HAVE A FOLLOW-UP QUESTION, IF
L 4	I COULD, ART. ON THAT POINT, WE DISCLOSED ALL THE
15	ONES THAT HAVE RECEIVED GRANTS.
16	MR. DROWN: CORRECT.
17	MR. ROTH: SO WHY DOES IT MATTER WHO
18	DIDN'T RECEIVE A GRANT?
19	MR. DROWN: I THINK IT MATTERS SO THAT
20	PARTICULARLY ONCE YOU GO INTO THE BUSINESS REALM OF
21	FUNDING WINNERS AND LOSERS, I THINK THE PUBLIC COULD
22	BENEFIT FROM THE OPPORTUNITY FROM SEEING THE TRENDS
23	AND TO SEE WHAT FLAVORS DIDN'T MAKE THE CUT. I
24	THINK IT ADDS A WAY FOR THE PUBLIC TO KEEP TRACK OF
25	HOW PUBLIC MONEY IS SPENT.
	27
	LI

1	CHAIRMAN TORRES: SO THE SUSPICION IS THE
2	FOUNDATION FOR THE QUESTION THEN, SUSPICION THAT
3	SOMETHING MAY NOT BE RIGHT?
4	MR. DROWN: NO. NO, NOT THE SUSPICION. I
5	THINK THAT'S LOADING IT UP. I THINK THE PRACTICE OF
6	PEOPLE APPLYING FOR CONTRACTS WITH PUBLIC AGENCIES,
7	EVERYBODY GETS TO SEE WHO THE APPLICANTS ARE AND
8	GETS TO SEE WHO THE BIDS ARE.
9	CHAIRMAN TORRES: JUST A QUESTION. I KNOW
10	YOU REVIEWED THE GENERAL SERVICES AGENCY. DO THEY
11	REVEAL APPLICANTS OR VENDORS THAT WERE NOT
12	SUCCESSFUL IN GETTING A CONTRACT WITH THE STATE?
13	MR. DROWN: I DON'T KNOW THAT.
14	CHAIRMAN TORRES: I THINK THE ANSWER IS
15	NO.
16	MR. ROTH: THAT'S WHY I WAS ASKING THE
17	QUESTION. AS LONG AS WE'RE DISCLOSING THE WINNERS,
18	I WOULD THINK FROM THAT YOU CAN DISCERN THE
19	PROPORTIONALITY OF THE MONEY THAT'S BEING GIVEN OUT,
20	WHERE IS IT GOING. I DON'T SEE HOW IT HELPS YOU TO
21	KNOW WHO DIDN'T RECEIVE THE MONEY. AND THAT'S
22	WHAT I THINK ART ASKED THE QUESTION VERY WELL AND
23	DON REED EARLIER. I CAN IMAGINE THAT YOU COULD SAY
24	IT'S A STATE AGENCY. WE'D LIKE TO KNOW EVERYBODY
25	THAT APPLIED FOR THE JOB AND WHO YOU REJECTED. I
	28

1	THINK, AGAIN, THAT WOULD BE INAPPROPRIATE.
2	CHAIRMAN TORRES: ALL RIGHT. MR. SHEEHY,
3	SAN FRANCISCO.
4	MR. SHEEHY: I JUST WANT TO MAKE A COMMENT
5	TO THE CONNECTICUT EXAMPLE BECAUSE I DON'T REALLY
6	THINK THAT'S A GOOD METRIC TO MEASURE. I HAVE
7	ENORMOUS RESPECT FOR THE GREAT STATE OF CONNECTICUT.
8	THAT'S WHERE MY HUSBAND IS FROM. JUST LOOK AT THE
9	NUMBER OF ACADEMIC INSTITUTIONS, RESEARCH
10	INSTITUTIONS THAT POTENTIALLY COULD COMPETE FOR
11	GRANTS. THE LEVEL OF CONFIDENTIALITY, I THINK
12	THERE'S ONLY TWO OR THREE IN THE STATE THAT WOULD
13	REALLY BE COMPETING. SO IT'S NOT LIKE REVEALING THE
14	NAMES OF INSTITUTIONS. I DON'T THINK THERE'S A LOT
15	OF MYSTERY THERE BECAUSE THERE'S JUST NOT THAT MANY
16	APPLICATIONS.
17	I THINK BECAUSE OF THE SCALE AND BECAUSE
18	OF THE NUMBER OF PLAYERS IN CONNECTICUT VERSUS WHAT
19	WE'RE DEALING WITH IN CALIFORNIA, I JUST DON'T THINK
20	THAT'S A VERY VALID EXAMPLE TO USE. I'M SURE
21	THEY'RE DOING GREAT SCIENCE AND THEIR PROCESS IS AN
22	INTERESTING EXPERIENCE, BUT IT JUST DOESN'T REALLY
23	MATCH THE SCALE OF WHAT WE'RE TRYING TO ACHIEVE.
24	CHAIRMAN TORRES: ANY OTHER COMMENTS
25	BEFORE WE MOVE TO ITEM NO. 8? ALL RIGHT.
	29

1	MS. SAMUELSON: LET ME JUST SAY QUICKLY, I
2	DON'T WANT TO BELABOR THIS, BUT I APPRECIATE
3	CLAIRE HELPED ME ARTICULATE MY OWN INSTINCTS ON THIS
4	AND I APPRECIATE THAT. I AGREE THAT I SEE THIS AS A
5	BALANCE. AND I THINK THAT THE COMPETING DESIRE TO
6	HAVE TRANSPARENCY, GIVEN THAT THIS IS THE USE OF
7	PUBLIC DOLLARS, AND I THINK ESPECIALLY BECAUSE IT
8	WAS AN INITIATIVE WITH GREAT PUBLIC INTEREST, IS AN
9	IMPORTANT ONE. BUT I AM PERSUADED THAT THERE ARE
10	TOO MANY OPEN QUESTIONS ABOUT WHAT NEGATIVE IMPACTS
11	THIS COULD HAVE ON OUR DESIRE TO ATTRACT THE MOST
12	ENTREPRENEURIAL AND INNOVATIVE RESEARCHERS TO PUT
13	THEIR TO RISK THEIR PROFESSIONAL FUTURES ON VERY
14	AGGRESSIVE ATTEMPTS TO TACKLE OUR MISSION, THAT WE
15	HAVE TO BE REAL CAREFUL WITH THIS BALANCE. SO I'M
16	THINKING THAT WE SHOULD, UNLESS WE'RE SURE THAT
17	THERE ISN'T A SEVERE IMPACT, BE MORE PROTECTIVE OF
18	THAT INFORMATION.
19	CHAIRMAN TORRES: ALL RIGHT. ITEM NO. 8,
20	POLL PEER REVIEWERS TO DETERMINE WHETHER THEY WOULD
21	RESIGN IF THEY WERE REQUIRED TO PUBLICLY DISCLOSE
22	THEIR FINANCIAL INTERESTS. IS THAT ARTICULATION ALL
23	RIGHT, JAMES?
24	MR. HARRISON: YES. THE LITTLE HOOVER
25	COMMISSION RECOMMENDED THAT CIRM SHOULD POLL ITS
	20

1	REVIEWERS ANONYMOUSLY ABOUT THEIR WILLINGNESS TO
2	PARTICIPATE IN THE REVIEW PROCESS IF THEIR FINANCIAL
3	INTERESTS WERE DISCLOSED PUBLICLY.
4	DR. TROUNSON: WE'RE PROPOSING TO TAKE AN
5	INFORMAL POLL OF THE GRANTS WORKING GROUP MEMBERS
6	AND ALTERNATES ATTENDING THE NEXT GRANTS WORKING
7	GROUP MEETING TO FIND OUT WHETHER THEY WOULD BE
8	WILLING TO CONTINUE SERVING IF, NO. 1, THE FINANCIAL
9	DISCLOSURE DOCUMENTS THEY'RE CURRENTLY REQUIRED TO
10	COMPLETE WERE MADE PUBLIC OR, TWO, THEY'RE TO
11	COMPLETE AND MAKE PUBLIC THE FORM 700. SO WE
12	THOUGHT THAT THAT WOULD BE A REASONABLE TEST OF HOW
13	THE REST OF THE GROUP IS LIKELY TO RESPOND.
14	CHAIRMAN TORRES: THANK YOU, DOCTOR.
15	A DIRECT QUESTION TO STUART. MY QUESTION IS WAS IT
16	YOUR INTENT THAT WE REVIEW THE FORM 700 THAT THEY
17	SHOULD SIGN AND COMPLETE? WAS THAT THE INTENT OF
18	THE LITTLE HOOVER COMMISSION BECAUSE IT WAS NOT
19	CLEAR FROM THE REPORT?
20	MR. DROWN: I THINK YOU HAVE THE ABILITY
21	ALREADY TO REVIEW THEIR FORM 700, SO IT'S FILED WITH
22	YOU.
23	CHAIRMAN TORRES: NO. IT'S NOT THE CASE.
24	THEY'RE NOT REQUIRED TO BECAUSE THEY'RE NOT ELECTED
25	OR APPOINTED, STUART. THEY'RE NOT REQUIRED TO FILE
	31
	J±

1	FORM 700. THERE'S A DIFFERENT DISCLOSURE FORM.
2	DOCTOR, WOULD YOU ARTICULATE WHAT THAT
3	DISCLOSURE FORM IS PRESENTLY?
4	DR. TROUNSON: MAYBE I CAN ASK PAT OR
5	JAMES. MAYBE JAMES.
6	MR. HARRISON: THE GRANTS WORKING GROUP
7	MEMBERS ARE PRESENTLY REQUIRED TO DISCLOSE FINANCIAL
8	INTERESTS, INCLUDING INVESTMENTS, INCOME OF \$5,000
9	OR MORE. THEY'RE ALSO REQUIRED TO DISCLOSE PERSONAL
10	AND PROFESSIONAL AFFILIATIONS THAT COULD CREATE A
11	CONFLICT.
12	CHAIRMAN TORRES: AND YOU WANT THOSE
13	DOCUMENTS TO BE MADE PUBLIC, STUART. IS THAT YOUR
14	POSITION?
15	MR. STERN: THIS IS ERIC STERN, LITTLE
16	HOOVER COMMISSION STAFF. THE REASON WE INCLUDED
17	THAT RECOMMENDATION IN THERE WAS IT ADDRESSES AN
18	ONGOING CONCERN THAT'S BEEN OUT THERE SINCE THE
19	INCEPTION OF THE
20	CHAIRMAN TORRES: WHO HAS EXPRESSED THIS
21	CONCERN? DO YOU KNOW? ORGANIZATIONS OR INDIVIDUAL
22	LEGISLATORS?
23	MR. STERN: IT WAS LITIGATED. AND IT'S
24	BEEN A SUBJECT OF STATE AUDIT REPORTS, THIS ISSUE OF
25	THE FINANCIAL DISCLOSURES OF THE PEER REVIEWERS. SO

32

FINANCIAL DISCLOSURES THAT THEY HAVE TO FILE WITH CIRM, BUT JUST POLL THEM. THE ARGUMENT IS MADE FROM
CIRM, BUT JUST POLL THEM. THE ARGUMENT IS MADE FROM
CIRM THAT YOU WOULD LOSE ALL OUR PEER REVIEWERS IF
THEY HAD TO IF THEIR FINANCIAL DISCLOSURES WERE
MADE PUBLIC. AND SO
CHAIRMAN TORRES: YOU WANT US TO MAKE SURE
BY ASKING THEM.
MR. STERN: THE LITTLE HOOVER COMMISSION
SAID WE'RE GOING TO PUT THAT BURDEN ON YOU TO PROVE
THAT. ASK THEM IF THEY'RE ACTUALLY GOING TO BACK
OUT.
CHAIRMAN TORRES: THAT'S WHAT WE INTEND TO
DO, STUART. ALL RIGHT. JUST WANTED TO BE CLEAR.
MR. SHEEHY.
MR. SHEEHY: IF I CAN MAKE A QUICK POINT.
WE ACTUALLY HAD A DISCUSSION OF THIS EARLIER ON, AND
WE ACTUALLY DID LOSE A REVIEWER BECAUSE WE HAD THE
DISCUSSION. SO, YOU KNOW, WE CAN REVALIDATE WHAT WE
KNOW TO BE TRUE. THIS WAS BROUGHT UP IN A PUBLIC
MEETING PRIOR TO THE AS PART OF THE STRATEGIC
PLANNING PROCESS. ONE OF THE INDIVIDUALS THERE SAID
IF THIS CAME UP IF I HAD TO DO THIS, I'D RESIGN.
AND THAT INDIVIDUAL IS NO LONGER A REVIEWER. THE
DISCUSSION OF IT WAS ENOUGH TO DISINCENTIVIZE THAT
33

1	REVIEWER. AND THE OTHER REVIEWERS IN THAT PUBLIC
2	MEETING AS PART OF THAT PROCESS ALL WERE FAIRLY
3	NEGATIVE ABOUT DOING THIS.
4	AND I DO THINK IT GOES TO THE POINT OF
5	WHAT THEIR ROLE IS. THEY ARE NOT DECISION MAKERS.
6	THEY MERELY MAKE RECOMMENDATIONS.
7	SO IT'S NOT INCONSISTENT WITH HOW THINGS
8	ARE DONE IN STATE GOVERNMENT TO NOT DISCLOSE ALL
9	THEIR FINANCIAL INTERESTS. AND, FRANKLY, THE
10	CONFLICT OF INTEREST POLICIES THAT THEY'RE HELD TO
11	ARE STRICTER THAN THOSE THAT WOULD BE REQUIRED BY A
12	FORM 700. AND TAKING INTO ACCOUNT THOSE KINDS OF
13	PROFESSIONAL RELATIONSHIPS THAT ACTUALLY WITHIN THE
14	ACADEMIC WITHIN THE RESEARCH WORLD MAY BE MORE
15	COMPELLING THAN THE ACTUAL FINANCIAL INCENTIVES THAT
16	TYPICALLY BECOME THE SOURCES OF CONFLICTS OF
17	INTEREST AND WHICH FORM 700 SPECIFICALLY TRY TO
18	ADDRESS.
19	CHAIRMAN TORRES: I THINK THAT IS AN
20	EXCELLENT POINT, MR. SHEEHY. AND I THINK THAT OUGHT
21	TO BE PART OF OUR RESPONSE TO THE LEGISLATURE, TO
22	LET THEM KNOW WE GO BEYOND COMMON PRACTICE IN
23	RESPECT TO ASKING FOR FINANCIAL DISCLOSURES IN ORDER
24	TO AVOID EVEN THE PERCEPTION OF CONFLICT. SO I
25	THINK THAT NEEDS TO BE PART OF OUR RESPONSE TO THIS
	34
	J T

1	QUESTION.
2	BE THAT AS IT MAY, WE ARE GOING TO CONDUCT
3	A POLL, AND IT WILL BE DONE APPROPRIATELY, AND WE
4	WILL RELEASE THE RESULTS PUBLICLY TO THE
5	LEGISLATURE.
6	ANY OTHER COMMENTS ON ITEM NO. 8?
7	MR. JENSON: ON THIS POLLING, IS IT GOING
8	TO BE DONE ANONYMOUSLY?
9	DR. TROUNSON: YES.
10	MR. JENSON: WHAT'S THE DIFFERENCE BETWEEN
11	AN INFORMAL POLL AND A FORMAL POLL?
12	DR. TROUNSON: IT WILL BE DONE DURING THE
13	GRANTS WORKING GROUP MEETING. IT WON'T BE DONE IN
14	PUBLIC, LET ME SAY, BUT WILL BE DONE ANONYMOUSLY
15	WITHIN THAT GRANTS WORKING GROUP MEETING, THE NEXT
16	ONE WE'RE HAVING.
17	MR. JENSON: OKAY.
18	MR. KLEIN: MAY I MAKE A MEMBER'S COMMENT.
19	I'D LIKE TO POINT OUT THAT SEPARATE FROM MEMBERS OF
20	THIS BOARD, THE CONTROLLER'S AUDIT FROM 2009 POINTS
21	OUT THAT OUR THREE LEVELS OF CONFLICTS CLEARANCES GO
22	SIGNIFICANTLY BEYOND THE NIH.
23	CHAIRMAN TORRES: THAT WAS MY POINT, BOB,
24	THAT WE'RE GOING TO INCLUDE THAT IN OUR RESPONSE TO
25	THE LEGISLATURE.

35

1	MR. KLEIN: BUT SECONDLY, WE HAVE A
2	PROCESS WHERE THE MONITORING OF THESE CONFLICTS, IF
3	THEY EXIST, FOR EXAMPLE, PROFESSIONAL CONFLICTS, AND
4	THE RECUSALS FROM THE PEER REVIEW WORKING GROUP ARE,
5	IN FACT, MONITORED INDIVIDUALLY ONE ON ONE BY STAFF
6	DURING THE PEER REVIEW PROCESS TO MAKE SURE IT TAKES
7	PLACE. THERE ARE RECORDS KEPT OF IT. AND THERE IS
8	A PROCESS FOR THE STATE AUDITING FUNCTION THROUGH
9	THE LEGISLATURE TO INSPECT THEM AND MAKE CERTAIN
10	THAT RECUSALS HAPPEN PROPERLY WITH A PROVISION FOR
11	REPORTS TO THE LEGISLATURE IF THEY DO NOT.
12	CHAIRMAN TORRES: ALL RIGHT.
13	MR. KLEIN: THE OVERSIGHT FUNCTION ON TOP
14	OF THE THOROUGHNESS OF THE CONFLICTS PROVISIONS WE
15	HAVE IN PLACE NOW.
16	CHAIRMAN TORRES: ANY OTHER COMMENTS FROM
17	MEMBERS OF THE COMMITTEE?
18	MS. SAMUELSON: AS WITH THE PREVIOUS
19	ISSUE, THERE'S AN IMPORTANT INTEREST THAT HAS TO BE
20	BALANCED WITH FINANCIAL DISCLOSURE. AND I FEEL WE
21	HAVE GONE, I REALLY FEEL PERSONALLY STRONGLY, GONE
22	WAY OVER IN THE DIRECTION OF EXTREME FINANCIAL
23	DISCLOSURE AND TO THE HARM OF OUR ABILITY TO GET THE
24	BEST AND THE BRIGHTEST SCIENTISTS FROM AROUND THE
25	WORLD TO PARTICIPATE IN OUR PEER REVIEW DISCUSSIONS
	36

1	SO THAT WE GET THE VERY BEST WORK PRODUCT OUT OF
2	THAT PROCESS. THEY WORK EXTREMELY HARD, LONG HOURS.
3	IT'S VERY DIFFICULT TO GET HERE AND TAKE THE TIME
4	AWAY FROM THEIR OWN CAREERS. AND I WOULD BE VERY
5	CONCERNED IF, AS JEFF SAID, THERE'S ANY KIND OF
6	HISTORY THAT THIS SORT OF THING COULD DISCOURAGE
7	THEM FROM EVEN BEING INVOLVED IN THE FUTURE.
8	CHAIRMAN TORRES: ALL RIGHT.
9	DR. PRIETO: QUESTION ABOUT BOB'S COMMENT
10	REGARDING THE AUDIT. DO THOSE AUDITORS HAVE ACCESS
11	TO THE ORIGINAL DATA, THE DOCUMENTS SUBMITTED BY THE
12	REVIEWERS?
13	CHAIRMAN TORRES: YES.
14	DR. PRIETO: THANK YOU.
15	CHAIRMAN TORRES: ANY OTHER PUBLIC
16	COMMENTS FROM SACRAMENTO? WE'RE GOING TO MOVE ON.
17	LA JOLLA?
18	MR. ROTH: NO.
19	CHAIRMAN TORRES: IRVINE?
20	DR. LEVIN: NO.
21	CHAIRMAN TORRES: HEALDSBURG? WE JUST
22	HEARD FROM JOAN. MOUNTAIN VIEW?
23	MR. GOLDBERG: NO.
24	CHAIRMAN TORRES: PALO ALTO? I THINK
25	WE'VE HEARD FROM PALO ALTO JUST RECENTLY. ALL
	27
	37

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	RIGHT. SAN FRANCISCO, ANY PUBLIC COMMENTS HERE.
2	THERE BEING NONE, WE'LL MOVE ON TO THE
3	NEXT ITEM, WHICH IS ITEM NO. 9, AMEND THE MINUTES OF
4	BOARD MEETINGS TO DISCLOSE VOTE TALLIES AND
5	RECUSALS. AND MR. JAMES HARRISON HAS A RESPONSE.
6	AND I BELIEVE ALL THE MEMBERS, YOU SHOULD HAVE A
7	DOCUMENT THAT WAS E-MAILED TO YOU OUTLINING THE VERY
8	ARTICULATE STATEMENT OF MR. HARRISON ON THIS MATTER
9	AND THE FOLLOWING MATTER, WHICH IS, AND I THINK WE
10	OUGHT TO TAKE THEM TOGETHER, IF YOU DON'T MIND,
11	MEMBERS, ITEMS NO. 9 AND 10 AND LET JAMES ADDRESS
12	THOSE AND WE'LL TAKE QUESTIONS.
13	MR. HARRISON: THANK YOU, CHAIRMAN TORRES.
14	AS ART STATED, THE LITTLE HOOVER COMMISSION HAS
15	RECOMMENDED THAT WE AMEND OUR MEETING MINUTES, WHICH
16	CURRENTLY IDENTIFY THE MOTIONS AND THE VOTES ON
17	THOSE MOTIONS FOR ALL GRANT ROUNDS. THE LITTLE
18	HOOVER COMMISSION HAS RECOMMENDED THAT WE INCLUDE
19	GREATER DETAIL BY ACTUALLY INCLUDING THE TALLIES AS
20	WELL AS THE RECUSALS FOR VOTES ON GRANT
21	APPLICATIONS.
22	SO IN LIGHT OF THAT RECOMMENDATION, WE
23	HAVE GONE BACK TO JANUARY 1, 2008, AND PRODUCED
24	SUMMARIES OF THE TALLIES AND RECUSALS FOR EACH VOTE
25	ON A GRANT APPLICATION AT EACH MEETING THAT HAS

1	OCCURRED. AND WE'D RECOMMEND THAT GOING FORWARD WE
2	INCLUDE IN THE MINUTES VOTE TALLIES AND RECUSALS AS
3	A MATTER OF COURSE.
4	CHAIRMAN TORRES: ALL RIGHT. COMMENTS ON
5	THAT ISSUE?
6	MR. KLEIN: AS CHAIRMAN OF THE BOARD, ART,
7	I'D LIKE THE MEMBERS TO KNOW THAT IN THE INTEREST OF
8	DISCLOSURE AND TRANSPARENCY, I FELT THIS WAS A VERY
9	GOOD RECOMMENDATION, BROUGHT IT UP AT THE EXECUTIVE
10	COMMITTEE, THE EXECUTIVE COMMITTEE SUPPORTED IT, AND
11	ASKED JAMES HARRISON AND INTERNAL COUNSEL TO REVIEW
12	LEGAL QUESTIONS. THERE WERE NONE. SO I ASKED FOR
13	IT TO BE IMPLEMENTED, AND IT IS, AS JAMES HAS SAID,
14	BEING IMPLEMENTED CURRENTLY.
15	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER
16	RESPONSE ON THIS ONE? I THINK WE'VE RESPONDED
17	PRETTY POSITIVELY.
18	DR. PRIETO: QUESTION, MR. CHAIRMAN.
19	AREN'T THE TRANSCRIPTS OF ALL OUR PREVIOUS MEETINGS
20	THAT HAVE BEEN KEPT AVAILABLE SOMEWHERE?
21	MS. KING: THEY'RE AVAILABLE ON THE
22	WEBSITE. THEY'RE AVAILABLE ON THE WEBSITE, AND THEY
23	HAVE BEEN SINCE JANUARY OF 2005. EVERY TIME THERE'S
24	A MEETING, THE TRANSCRIPT OF THAT MEETING, INCLUDING
25	ALL OF THE ROLL CALL VOTES AND THE NOTATION OF VOICE
	30

1	VOTES, ARE AVAILABLE ON THE WEBSITE WITHIN, I'D SAY,
2	AT MOST A MONTH AFTER THE MEETING, OFTEN MUCH SOONER
3	THAN THAT, AND THEY'VE BEEN ON THE WEBSITE SINCE
4	JANUARY OF 2005.
5	CHAIRMAN TORRES: EVERY MINUTES OF BOARD
6	MEETINGS SINCE 2005.
7	MS. KING: TRANSCRIPTS, ACTUALLY VERBATIM.
8	CHAIRMAN TORRES: VERBATIM TRANSCRIPTS FOR
9	THOSE WHO WANT TO READ ARE AVAILABLE ON THE WEBSITE.
10	MS. KING: THAT'S RIGHT.
11	CHAIRMAN TORRES: EVERY LITTLE NUANCE BY
12	EVERY BOARD MEMBER IS NOW IN THAT THAT'S A
13	WARNING TO ALL OF US TO KEEP OUR COMMENTS BRIEF AND
14	TO THE POINT.
15	MR. HARRISON: INCLUDING WHAT YOU SAID
16	JUST NOW, CHAIRMAN TORRES.
17	CHAIRMAN TORRES: ALL RIGHT. IF THERE ARE
18	NO OTHER COMMENTS, WE'LL MOVE ON
19	DR. POMEROY: ONE MORE COMMENT.
20	MR. JENSON: WE HAVE A COMMENT HERE. DAVE
21	JENSON WITH THE CALIFORNIA STEM CELL REPORT AGAIN.
22	WE SHOULD NOTE THAT THE TRANSCRIPTS DO NOT CONTAIN
23	VOTE TALLIES IN MANY CASES, AND IT IS OFTEN
24	IMPOSSIBLE TO DETERMINE AN INDIVIDUAL MEMBER'S VOTE
25	FROM THE TRANSCRIPTS AND/OR THE MINUTES OR ANY
	40

1	PUBLIC RECORDS ACT REQUEST FROM A MEMBER OF THE
2	PUBLIC.
3	CHAIRMAN TORRES: WHO WAS IT?
4	MR. HARRISON: DAVE JENSON.
5	CHAIRMAN TORRES: WE WANT TO GIVE YOU
6	CREDIT, BUDDY.
7	MR. JENSON: OKAY.
8	CHAIRMAN TORRES: ANY OTHER COMMENTS FROM
9	SACRAMENTO BEFORE WE CLOSE THE LINE THERE? LA
10	JOLLA?
11	MR. ROTH: NO.
12	CHAIRMAN TORRES: IRVINE?
13	DR. LEVIN: NO.
14	CHAIRMAN TORRES: SAN FRANCISCO, ANY
15	PUBLIC COMMENT ON THIS ISSUE? NONE. HEALDSBURG?
16	JOAN, DID YOU HAVE ANYTHING ELSE TO ADD?
17	MS. SAMUELSON: NOTHING.
18	CHAIRMAN TORRES: MOUNTAIN VIEW? PALO
19	ALTO, WE'VE HEARD OUR CHAIRMAN, MR. KLEIN.
20	WE'LL MOVE ON TO ITEM NO. 10, WHICH IS ADD
21	A PROVISION TO THE BOARD BYLAWS AUTHORIZING THE
22	REMOVAL OF MEMBERS FOR CAUSE. MR. HARRISON.
23	MR. HARRISON: THAT'S AN ACCURATE SUMMARY
24	OF THE LITTLE HOOVER COMMISSION'S RECOMMENDATION.
25	THE PROBLEM WITH THIS PARTICULAR RECOMMENDATION IS
	42

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THAT THE BOARD DOES NOT HAVE THE POWER THROUGH ITS
2	BYLAWS TO ADOPT A REMOVAL PROVISION. UNDER PROP 71
3	MEMBERS SERVE FIXED TERMS. AND THE COURT OF
4	APPEALS, IN UPHOLDING PROP 71 AGAINST A
5	CONSTITUTIONAL CHALLENGE, CONSTRUED THIS PROVISION,
6	CONSISTENT WITH CALIFORNIA LAW, TO MEAN THAT MEMBERS
7	ARE NOT SUBJECT TO REMOVAL BY THEIR APPOINTING
8	AUTHORITY. AND THAT READING IS CONSISTENT WITH
9	CALIFORNIA LAW, WHICH SPECIFIES THAT A MEMBER IS
10	SUBJECT TO REMOVAL BY THE APPOINTING AUTHORITY ONLY
11	WHEN THE MEMBER'S TERM IS NOT PRESCRIBED BY LAW.
12	WELL, PROP 71 VERY EXPLICITLY SETS THE
13	TERMS OF MEMBERS, SO THERE'S NO POWER OF REMOVAL
14	EXCEPT THROUGH A QUO WARRANTO ACTION INITIATED BY
15	THE ATTORNEY GENERAL. NOR DOES PROP 71 PROVIDE THE
16	ICOC WITH THE POWER TO REMOVE MEMBERS. IN FACT, IF
17	THE ICOC WERE TO INCLUDE SUCH A PROVISION IN ITS
18	BYLAWS, IT WOULD BE INTRUDING UPON THE AUTHORITY OF
19	THE APPOINTING POWERS TO DESIGNATE WHOM THEY WISH TO
20	SERVE ON THEIR BEHALF.
21	SO AS A MATTER OF LAW, THE BOARD SIMPLY
22	DOESN'T HAVE AUTHORITY TO ADD SUCH A PROVISION TO
23	ITS BYLAWS; OR IF IT DID, IT WOULDN'T BE
24	ENFORCEABLE.
25	CHAIRMAN TORRES: THEREFORE, IN REALITY IT

1	WOULD BE UP TO THE APPOINTING POWER TO SUGGEST TO
2	THE MEMBER, IF THEY DIDN'T FEEL THEY'RE PERFORMING
3	THEIR DUTIES PROPERLY, TO PLEASE SUBMIT THEIR LETTER
4	OF RESIGNATION.
5	MR. HARRISON: THAT'S CORRECT. THE POWER
6	OF PERSUASION.
7	CHAIRMAN TORRES: THE POWER OF PERSUASION.
8	ALL RIGHT. ANY COMMENTS FROM SACRAMENTO ON THAT
9	POINT?
10	DR. PRIETO: DOES ANYONE HAVE THE POWER?
11	I THINK YOU ALLUDED TO THE ATTORNEY GENERAL.
12	MR. HARRISON: THE ATTORNEY GENERAL HAS
13	THE POWER UNDER A PROCEDURE THAT'S KNOWN AS QUO
14	WARRANTO.
15	DR. POMEROY: I JUST WANT TO SAY THAT I
16	THINK IT'S WORRISOME THAT WE CAN'T REMOVE MEMBERS
17	FOR CAUSE. AND I RESPECT THE LEGAL INTERPRETATION.
18	AND, YOU KNOW, WHAT IS IS. BUT I THINK THAT THIS IS
19	A LESSON LEARNED FOR US FOR THE FUTURE, WHICH IS
20	THAT AS A BOARD, MAKING SURE THAT WE ARE ALL DOING
21	OUR JOB IN A RESPONSIBLE, ETHICAL WAY IS A BIG PART
22	OF IT. AND SO I JUST WANT TO BE ON THE RECORD AS
23	SAYING I THINK IT'S VERY UNFORTUNATE THAT THE LEGAL
24	INTERPRETATION IS THAT WE'RE NOT ABLE TO DO
25	SOMETHING ABOUT THIS.

CHAIRMAN TORRES: THAT PROMPTS A QUESTION,
MR. HARRISON. WHAT IF THE MAJORITY OF THE BOARD
DECIDED TO SOLICIT THE ATTORNEY GENERAL IN AN
ACTION?
MR. HARRISON: THE BOARD COULD CERTAINLY
DO SO, AND IT WOULD BE UP TO THE ATTORNEY GENERAL TO
DECIDE WHETHER TO INITIATE AN ACTION DIRECTLY OR TO
LET THE BOARD INITIATE ITS OWN ACTION TO REMOVE A
MEMBER.
CHAIRMAN TORRES: SO AT THE END OF THE
DAY, THERE IS NO SOLID CONCRETE BARRIER FOR US
SEEKING REDRESS IN THE REMOVAL OF A MEMBER?
MR. HARRISON: THAT'S RIGHT. IT'S JUST
THAT THE BOARD COULDN'T DO SO UNILATERALLY. IT
WOULD HAVE TO ASK THE ATTORNEY GENERAL TO INTERVENE
ON ITS BEHALF.
I SHOULD ALSO POINT OUT, JUST SO THE
RECORD IS CLEAR, THIS FEATURE, WHETHER IT'S A WISE
POLICY OR NOT, IS NOT UNIQUE TO THIS BOARD. THERE
ARE MANY BOARDS IN STATE GOVERNMENT WHOSE MEMBERS
SERVE FIXED TERMS AND WHO ARE NOT SUBJECT TO
REMOVAL. THE CALIFORNIA MEDICAL ASSISTANCE
COMMISSION, FOR EXAMPLE, THE FIRST FIVE COMMISSIONS,
I BELIEVE EVEN THE LITTLE HOOVER COMMISSION.
MR. DROWN: YOU CAN BE REMOVED FOR CAUSE

1	FROM THE LITTLE HOOVER COMMISSION.
2	CHAIRMAN TORRES: OH, THE LITTLE HOOVER
3	COMMISSION MEMBER CAN BE REMOVED FOR CAUSE?
4	MR. DROWN: YES. AND THEY CAN BE REMOVED
5	FOR MISSING THREE MEETINGS.
6	MR. HARRISON: STUART, I BELIEVE THAT'S A
7	PROVISION THAT'S IN THE BOARD'S BYLAWS AND IS NOT BY
8	STATUTE. IF I'M NOT CORRECT, MEMBERS SERVE FIXED
9	TERMS; IS THAT RIGHT?
10	MR. DROWN: CORRECT.
11	MR. KLEIN: WE BELIEVE THAT THAT PROVISION
12	IS NOT CONSTITUTIONAL.
13	CHAIRMAN TORRES: SO THERE'S NEVER BEEN A
14	LITTLE HOOVER COMMISSION MEMBER THAT I RECALL IN 30
15	YEARS OF PUBLIC SERVICE BEING REMOVED OR EVEN
16	QUESTIONED. THE ONLY QUESTION IS WHY DO THEY WANT
17	TO SERVE ON THIS COMMITTEE. THAT'S THE ONLY
18	QUESTION THAT'S BEEN POSED TO PEOPLE BECAUSE OF THE
19	LENGTH OF TIME THAT IT REQUIRES. MY KUDOS TO THE
20	STAFF FOR PUTTING UP WITH THE TIME THAT'S REQUIRED.
21	DR. POMEROY: JAMES, I'D JUST LIKE TO
22	THANK YOU FOR THAT CLARIFICATION BECAUSE I ACTUALLY
23	DO FIND IT REASSURING THAT THERE IS A PATH, ALBEIT
24	PERHAPS A CIRCUITOUS ONE, BUT IT IS IMPORTANT TO
25	KNOW THAT THERE IS A PATH. THANK YOU.

1	MR. KLEIN: DR. POMEROY, THE BALANCING OF
2	THIS IS THAT BY HAVING AN OBJECTIVE THIRD PARTY, THE
3	ATTORNEY GENERAL, WHO HAS TO DECIDE WHETHER THERE'S
4	APPROPRIATE CAUSE, PROTECTS THE ABILITY TO HAVE
5	APPOINTMENTS TO THE BOARD THAT REPRESENT THE
6	APPOINTING AUTHORITY PERSPECTIVE WITHOUT HAVING TO
7	BE UNDERMINED BECAUSE THE MAJORITY OF THE BOARD MAY
8	DISAGREE WITH THAT POINT OF VIEW. SO IT GIVES AN
9	OBJECTIVE PROTECTION TO THE VOTERS AND TO THE AGENCY
10	THAT CAUSE WILL REALLY MEAN CAUSE.
11	CHAIRMAN TORRES: ANY OTHER COMMENTS?
12	MR. JENSON: DAVE JENSON. PERHAPS JAMES
13	COULD ANSWER THIS. AND THE QUESTION IS IS THERE
14	ANYTHING TO PREVENT THE BOARD FROM VOTING TO ASK A
15	MEMBER TO RESIGN FOR CAUSE OR WITHOUT CAUSE?
16	MR. HARRISON: NO. THERE'S NOTHING THAT
17	WOULD PREVENT THE BOARD FROM TAKING UP A MOTION TO
18	ASK A MEMBER TO RESIGN.
19	CHAIRMAN TORRES: ALL RIGHT. I THINK
20	WE'RE READY TO MOVE ON TO THE NEXT ITEM IF WE CAN.
21	MS. SAMUELSON: I'D SAY THAT CLAIRE
22	ARTICULATED MY VIEW ON THIS PRECISELY.
23	CHAIRMAN TORRES: THANK YOU. ITEM NO. 11,
24	ADOPT A SUCCESSION PLAN FOR LEADERSHIP AND A
25	TRANSITION PLAN FOR THE EVENTUAL EXPIRATION OF BOND
	47
	17

1	FUNDING. IS THAT AN ACCURATE STATEMENT? THAT IS AN
2	ACCURATE STATEMENT. I BELIEVE MR. KLEIN HAS A
3	RESPONSE.
4	MR. KLEIN: SO THE INTENTION HERE IS TO
5	HAVE A, FIRST OF ALL, IN TERMS OF BOND FUNDING,
6	STRATEGIC FINANCIAL PLAN THAT WILL BE ISSUED THIS
7	FALL TO THE BOARD FOR DISCUSSION AND DRAFT AND THEN
8	RECONSIDERED IN THE WINTER PERIOD.
9	THERE ARE A NUMBER OF OPTIONS THAT WILL
10	HINGE ON THE PERFORMANCE OF THE AGENCY BECAUSE
11	CERTAINLY IF THE AGENCY HAS PERFORMED, I BELIEVE THE
12	PUBLIC, LIKE THE CALIFORNIA HOUSING FINANCE AGENCY,
13	WILL SEE THE OPPORTUNITY AND THE VALUE OF PROVIDING
14	GREATER BOND AUTHORITY SO THIS AGENCY CAN CONTINUE
15	ITS GOOD WORK. IF THE AGENCY HASN'T PERFORMED, IT'S
16	A GOOD OPPORTUNITY FOR THE PUBLIC TO HOLD IT
17	ACCOUNTABLE AND NOT CONTINUE THE CHARTER BY NOT
18	PROVIDING MORE FUNDING.
19	AS TO THE LEADERSHIP, BY ANNOUNCING EARLY,
20	18 MONTHS BEFORE THE END OF MY TERM, MY INTENTION
21	NOT TO SEEK REAPPOINTMENT, IT PROVIDES SUBSTANTIAL
22	TIME TO WORK WITH THE BOARD POTENTIALLY HAVING A
23	SEARCH COMMITTEE FOR THE CHAIR WHICH COULD MAKE
24	RECOMMENDATIONS TO THE APPOINTING AUTHORITIES. THEY
25	WOULD BE FREE IN THEIR SOLE DISCRETION TO CONSIDER

1	THOSE RECOMMENDATIONS OR NOT. BUT WE HAVE THE TIME
2	AND WE ARE IN THE PROCESS OF THINKING THROUGH THE
3	SUCCESSION PLAN. WE'LL BRING SUCH A SUCCESSION PLAN
4	TO THE BOARD. AND THAT IS THE CURRENT STATUS.
5	CHAIRMAN TORRES: ANY COMMENTS FROM
6	MEMBERS OF THE COMMITTEE? ANY PUBLIC COMMENTS IN LA
7	JOLLA?
8	MR. ROTH: NO.
9	CHAIRMAN TORRES: IRVINE?
10	DR. LEVIN: NO.
11	CHAIRMAN TORRES: PALO ALTO WE'VE HEARD.
12	MOUNTAIN VIEW? JOAN SAMUELSON?
13	MS. SAMUELSON: I THINK THIS IS ONE
14	INSTANCE WHERE WE REALLY ARE DIFFERENT FROM IF
15	THERE'S ANY SUCH THING AS A CONVENTIONAL STATE
16	AGENCY. BUT MANY SOURCES OF FUNDING THAT WE'VE BEEN
17	ABLE TO ATTRACT, LARGELY WITH THE HARD WORK OF
18	CHAIRMAN KLEIN, MAKES US DIFFERENT.
19	CHAIRMAN TORRES: THANK YOU, JOAN. ANYONE
20	ELSE IN SACRAMENTO?
21	DR. POMEROY: I JUST WANT TO SAY I THINK
22	IT'S THE BOARD'S RESPONSIBILITY TO HAVE A SUCCESSION
23	PLAN FOR LEADERSHIP, AND I THINK THAT'S WHAT BOB
24	JUST SAID. AND I THINK IT'S THE BOARD'S
25	RESPONSIBILITY TO HAVE A TRANSITION PLAN OR AT LEAST
	49

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	A DEFINITION OF WHAT WE'LL DO AFTER THERE'S NO
2	MONEY. AND THAT'S KIND OF THE DEFINITION OF THE
3	ROLE OF THIS BOARD.
4	CHAIRMAN TORRES: EXACTLY. WELL PUT,
5	CLAIRE. ANY COMMENTS HERE IN SAN FRANCISCO FROM THE
6	PUBLIC? ANY MEMBERS? ALL RIGHT. WE'LL PROCEED TO
7	ITEM NO. 12. CAN YOU READ THAT FOR US, MR.
8	HARRISON?
9	MR. HARRISON: THE LITTLE HOOVER
10	COMMISSION HAS RECOMMENDED THAT THE LEGISLATURE
11	SHOULD AMEND PROP 71 TO REMOVE THE 50-PERSON CAP ON
12	CIRM STAFFING.
13	CHAIRMAN TORRES: MR. PRESIDENT.
14	DR. TROUNSON: CURRENTLY CIRM IS
15	CHALLENGED BY THE 50-EMPLOYEE CAP, AND WE'RE
16	CURRENTLY REVIEWING THIS MATTER, BUT REMAIN
17	COMMITTED TO KEEPING WITHIN THE 6-PERCENT CAP ON USE
18	OF BOND FUNDS FOR ADMINISTERING THE EXPENDITURES.
19	CHAIRMAN TORRES: ANY COMMENTS FROM
20	MEMBERS OF THE COMMITTEE? PUBLIC COMMENTS IN
21	SACRAMENTO?
22	DR. POMEROY: THIS IS CLAIRE. YOU KNOW, I
23	THINK THIS IS POTENTIALLY AN OPPORTUNITY FOR US TO
24	BE A LITTLE MORE PROACTIVE PERHAPS IN THIS RESPONSE.
25	YES, OF COURSE, WE NEED TO REVIEW THIS. BUT HAVEN'T

1	WE KIND OF REVIEWED THE IMPACT OF THE 50-EMPLOYEE
2	CAP FOR LIKE SINCE THE BEGINNING OF OUR EXISTENCE?
3	AND HERE'S AN EXAMPLE, I THINK, OF A PLACE WHERE
4	WE'RE VERY ALIGNED WITH THE LITTLE HOOVER COMMISSION
5	RECOMMENDATION OR SUGGESTION.
6	SO I WOULD BE VERY INTERESTED IN US AS A
7	BOARD, YOU KNOW, AS SOON AS WE'RE DONE WITH THE
8	REVIEW, ENDORSING THE CONCEPT THAT IT'S GOOD TO
9	LIMIT YOUR ADMINISTRATIVE EXPENSES.
10	CHAIRMAN TORRES: RIGHT.
11	DR. POMEROY: AND WE AGREE WITH THAT CAP,
12	BUT AN ARTIFICIAL NUMBER ON THE NUMBER OF EMPLOYEES
13	SEEMS UNHELPFUL. SO IF THERE'S SOME WAY TO
14	ELIMINATE THAT, I'D LIKE US TO PROACTIVELY
15	INVESTIGATE THAT.
16	CHAIRMAN TORRES: WELL, THE ONLY
17	ALTERNATIVE TO DOING THAT IS TO INTRODUCE
18	LEGISLATION, WHICH RESULTS IN ITS OWN PRECARIOUS
19	IMPACTS.
20	MR. KLEIN: I WOULD ALSO LIKE TO SAY THAT
21	PAYING FOR EMPLOYEES OUTSIDE OF STATE FUNDS IS A
22	POSSIBILITY THAT WE'RE LOOKING AT, WHETHER IT'S
23	DONATIONS OR OTHER SOURCES. WHAT'S VERY IMPORTANT
24	IS TO MAKE SURE THE TAXPAYERS' MONEY IS GOING TO
25	RESEARCH AND THAT 94 CENTS OUT OF EVERY DOLLAR GOES

1	TO RESEARCH. BUT IT'S VERY IMPORTANT WITH TAXPAYER
2	FUNDS TO STAY WITHIN THAT 50-PERSON CAP, I THINK,
3	BUT I THINK THERE ARE SOME OPPORTUNITIES THAT WE'LL
4	REPORT BACK TO THE BOARD ON. IT IS A CHALLENGE, AS
5	CLAIRE POINTS OUT, BUT I THINK WE MAY HAVE MORE
6	PATHWAYS TO ADDRESS THAT.
7	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER
8	COMMENTS FROM SACRAMENTO? DR. POMEROY, DID YOU HAVE
9	A REBUTTAL FOR THAT?
10	DR. POMEROY: NO. I THINK THERE'S NO NEED
11	TO REBUT. WE AGREE.
12	CHAIRMAN TORRES: ALL RIGHT. ANYONE ELSE
13	IN SACRAMENTO?
14	MR. JENSON: I HAVE A COMMENT.
15	CHAIRMAN TORRES: WHO IS I?
16	MR. JENSON: I'M SORRY. DAVE JENSON. THE
17	50-PERSON CAP HAS BEEN A PROBLEM FOR A LONG TIME,
18	AND I THINK YOU GUYS ALL KNOW IT. IT REALLY HAS
19	BEEN A BIT OF A STRANGLE ON THE AGENCY, AND IT WOULD
20	BE A GOOD THING TO REMOVE IT. BUT AS YOU SAY,
21	LEGISLATION IS PRECARIOUS.
22	CHAIRMAN TORRES: YOU KNOW THAT BETTER
23	THAN ANYBODY. ANY OTHER COMMENTS FROM LA JOLLA?
24	MR. ROTH: NO.
25	CHAIRMAN TORRES: IRVINE?

1	DR. LEVIN: NO.
2	CHAIRMAN TORRES: PALO ALTO WE'VE HEARD.
3	MOUNTAIN VIEW?
4	MR. GOLDBERG: NO.
5	CHAIRMAN TORRES: HEALDSBURG?
6	MS. SAMUELSON: I AGREE WITH DAVE JENSON.
7	CHAIRMAN TORRES: ALL RIGHT. IN SAN
8	FRANCISCO, ANY PUBLIC COMMENTS HERE? THERE BEING
9	NONE, WE'LL PROCEED TO THE NEXT ITEM THEN.
10	ITEM NO. 13, WHICH WAS TO ELIMINATE THE
11	15-SCIENTIST CAP ON THE GWG. MR. PRESIDENT.
12	MR. HARRISON: I THINK THAT'S AN ADEQUATE
13	SUMMARY OF THE LITTLE HOOVER COMMITTEE'S
14	RECOMMENDATION.
15	DR. TROUNSON: WE'VE CONSIDERED THIS VERY
16	CAREFULLY AND FOR QUITE A LONG TIME. I THINK THE
17	IMPORT OF IT WAS TO BE ABLE TO UNRESTRICT US IN
18	DOING A MUCH LARGER NUMBER OF GRANT REVIEWS IN THE
19	NORMAL WAY WE DO IT, BUT THERE'S A REAL PROBLEM IN
20	DWELLING IN IT. IF YOU ELIMINATE A CAP OF 15
21	MEMBERS AND ALTERNATES PARTICIPATING IN A WORKING
22	GROUP MEETING, YOU WILL ACTUALLY NOT SIGNIFICANTLY
23	AFFECT THE GRANTS WORKING GROUP CAPACITY TO REVIEW
24	MORE GRANT APPLICATIONS, IN OUR VIEW. THE REAL
25	LIMITING FACTOR FOR REVIEW IS TIME.
	53
	J J

AT A REVIEW MEETING, THE GRANTS WORKING
GROUP CAN ONLY DISCUSS AND SCORE ABOUT 50 TOTAL
APPLICATIONS PER DAY FOR REGULAR RESEARCH GRANTS AND
PERHAPS 15 OR 20 FOR LARGER PROPOSALS, SUCH AS THE
DISEASE TEAMS OR TRAINING GRANTS.
AND IT'S JUST THAT WE REQUIRE A REASONABLE
IN-DEPTH DISCUSSION TO REALLY GET AT THE CORE OF THE
ISSUES IN THESE GRANTS. IF WE INCREASE THE NUMBER
OF GRANTS WORKING GROUP MEMBERS AT THE REVIEW,
YOU'LL NOT SPEED UP THE RATE WHICH THE APPLICATIONS
ARE REVIEWED. YOU'LL ACTUALLY SLOW IT BECAUSE YOU
NEED MORE PEOPLE WILL NEED TO DISCUSS IT
INDIVIDUALLY. IN FACT, IT MAY INCREASE THE REVIEW
TIME TO ACCOMMODATE DISCUSSION BY ALL ADDITIONAL
MEMBERS.
REGARDLESS OF THE NUMBER OF PARTICIPATING
GRANTS WORKING GROUP MEMBERS, REVIEW OF ADDITIONAL
APPLICATIONS WILL REQUIRE ADDITIONAL MEETING DAYS
AND INCREASE IN STAFF TIME TO MANAGE THE REVIEWS AND
THE WRITE-UPS OF THE SUMMARIES. WE BELIEVE, BASED
ON COMMENTS FROM REVIEWERS, THAT A LARGER GROUP
WOULD BE LESS FOCUSED AND ENGAGED AND THE LONGER
MEETINGS LEAD TO REDUCED WILLINGNESS TO ATTEND.
SO DESPITE WHAT I THINK WAS INTENTIONALLY
MEANT TO BE HELPFUL, IN OUR OWN ANALYSIS OF THE
54

1	SITUATION, WE THINK IT'S UNLIKELY TO ACTUALLY BE
2	HELPFUL. AND THAT, INTERESTINGLY, THE NUMBER OF
3	ABOUT 15 REVIEWERS, WE CAN ACCOMMODATE AND IT IS, AS
4	I JUDGE IT, AND I THINK MOST PEOPLE WHO ARE INVOLVED
5	IN THE GRANTS WORKING GROUP WOULD JUDGE IT TO BE A
6	FAIR AND REASONABLE PROCESS, AND THE TIME COMMITMENT
7	IS NOT UNREASONABLE.
8	CHAIRMAN TORRES: THANK YOU, MR.
9	PRESIDENT. MR. SHEEHY HERE IN SAN FRANCISCO, AND
10	THEN WE'LL MOVE TO SACRAMENTO.
11	MR. SHEEHY: I REALLY THINK THIS IS AN
12	INSTANCE OF IF IT'S NOT BROKE, WE DON'T NEED TO FIX
13	IT. AND I THINK THE PRESIDENT IS BEING UNDULY
14	MODEST ABOUT THE WAY THE PROCESS IS RUN AND ABOUT
15	THE EXTRAORDINARY EFFORTS OF STAFF. I SAT IN EVERY
16	REVIEW SESSION. THE QUALITY OF THE REVIEWS, THE
17	QUALITY AND THE DILIGENCE OF THE REVIEWERS, THE WORK
18	OF STAFF HAS BEEN TREMENDOUS. SO IF THEY SEE NO
19	THIS IS REALLY A MECHANICAL ISSUE. IF THIS WORKS
20	FOR THEM, I THINK WE SHOULD NOT INTERFERE WITH IT AT
21	ALL BECAUSE THE PRODUCT HAS BEEN SUPERB. I CAN'T
22	IMAGINE IT BEING DONE IN A BETTER WAY WITH MORE
23	INTEGRITY, WITH MORE DILIGENCE.
24	AND WE REALLY OWE STAFF AND THOSE
25	REVIEWERS A TREMENDOUS AND THE PEOPLE OF
	55
	· · · · · · · · · · · · · · · · · · ·

1	CALIFORNIA OWE THEM A TREMENDOUS VOTE OF THANKS
2	BECAUSE THEY'VE RUN A PRISTINE PROCESS.
3	CHAIRMAN KLEIN: THANK YOU, MR. SHEEHY.
4	SACRAMENTO? DR. POMEROY? DR. PRIETO?
5	DR. PRIETO: NO. I AGREE WITH JEFF.
6	CHAIRMAN TORRES: ALL RIGHT. ANY PUBLIC
7	COMMENTS THERE? LA JOLLA?
8	MR. ROTH: NO.
9	CHAIRMAN TORRES: IRVINE?
10	DR. LEVIN: THIS IS JACOB LEVIN FROM
11	IRVINE. I ACTUALLY HAVE TWO QUICK QUESTIONS. ONE
12	IS IF WE WERE TO CHANGE THE 15-MEMBER CAP OF THE
13	GRANTS WORKING GROUP, WOULD THAT HAVE TO BE DONE BY
14	A BALLOT INITIATIVE?
15	DR. TROUNSON: IT WOULD HAVE TO BE BY
16	LEGISLATURE, AND IT WOULD HAVE TO BE ARGUED TO BE OF
17	BENEFIT TO THE WHOLE PROCESS. SO, NO. 1, WE'D HAVE
18	TO ARGUE THAT IT WOULD BE STRONGLY BENEFICIAL AND
19	THEN, B, IT WOULD HAVE TO BE THEN INCORPORATED
20	WITHIN NEW LEGISLATION.
21	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER
22	COMMENTS FROM SACRAMENTO? PALO ALTO?
23	MR. KLEIN: FIRST OF ALL, FOR JACOB. IT'S
24	A MATTER OF DEGREE AS TO WHETHER IT CAN BE DONE BY
25	LEGISLATION. IF IT'S A SLIGHT ADJUSTMENT AND IS AN

1	ENHANCEMENT, THAT'S ONE THING. IF IT WAS A MAJOR
2	CHANGE, IT MIGHT BE MORE SIGNIFICANTLY IN QUESTION.
3	BUT REALIZE THAT ON TOOLS AND TECHNOLOGIES, WE HAD
4	BACK-TO-BACK 15-MEMBER PANELS. SO WHEN THERE WAS A
5	LARGE NUMBER OF GRANTS AND WE WERE CONSTRAINED IN
6	TIME THAT REVIEWERS WOULD SERVE, WE CREATED A PANEL
7	THAT DID GROUP A AND THEN A PANEL THAT DID GROUP B,
8	AND THE BOARD CONSIDERED BOTH PANELS'
9	RECOMMENDATIONS TOGETHER.
10	SO THERE IS FLEXIBILITY TO ADD ADDITIONAL
11	PANELS WITH EACH LIMITED TO 15 PERSONS SERVING AT
12	ONE TIME.
13	THE OTHER POINT I'D LIKE TO MAKE IS THAT
14	THERE'S SEVEN PATIENT ADVOCATES THAT SERVE ON THE
15	PEER REVIEW PROCESS. IF FOUR OR FIVE ARE PRESENT IN
16	REVIEWS, THAT MEANS THERE'S 19 TO 20 INDIVIDUALS
17	THAT ARE PARTICIPATING IN THE PROGRAMMATIC REVIEW OF
18	THE GRANTS. AND YOU HAVE TO CONSIDER THE INPUT OF
19	THAT NUMBER OF PEOPLE IN DETERMINING WHETHER YOU
20	HAVE ADEQUATE TIME FOR MEANINGFUL PARTICIPATION.
21	SO I AGREE WITH JEFF. I'VE BEEN AT EVERY
22	PEER REVIEW FROM THE BEGINNING. IT'S EXTRAORDINARY
23	WHAT THE STAFF HAS ACCOMPLISHED AND WHAT REVIEWERS
24	AROUND THE COUNTRY HAVE ACCOMPLISHED, PARTICULARLY
25	BECAUSE, UNLIKE ANY OTHER REVIEW GROUP IN THE WORLD,

1	THESE REVIEWERS, WE MUST REMEMBER, ARE ALL FROM
2	OUTSIDE OF CALIFORNIA. UNLIKE THE NIH, THESE
3	REVIEWERS CANNOT QUALIFY FOR A GRANT FROM THE SAME
4	PANEL THEY SIT ON. AND SO THEIR COMMITMENT TO TIME
5	ON THESE PANELS IS SOMETHING THAT IS A REAL
6	SACRIFICE WITHOUT ANY OF THE UPSIDES OF DEVELOPING
7	RELATIONSHIPS ON PANELS THAT EXIST AT THE NIH AND
8	OTHER INSTITUTIONS.
9	DR. LEVIN: YOU SPOKE TO, I GUESS, MY
10	OTHER QUESTION, WHICH IS COULD YOU SET UP SEVERAL
11	PARALLEL GRANTS WORKING GROUPS TO POTENTIALLY HAVE A
12	HIGHER THROUGHPUT OF GRANTS REVIEWED OR RECRUIT A
13	BROAD ENOUGH EXPERTISE TO COVER EVERYTHING IN A
14	GIVEN SET OF GRANTS BECAUSE SOMETIMES THE CALLS CAN
15	BE VERY WIDE-RANGING IN TERMS OF SCIENTIFIC OR EVEN
16	TECHNICAL OR BUSINESS EXPERTISE NEEDED TO REVIEW
17	THEM FROM START TO FINISH. BUT SOUNDS LIKE THAT
18	WITHIN THE RULES AS THEY ARE NOW WE CAN DO THAT.
19	MR. KLEIN: WE CERTAINLY CAN. AND THE
20	PANEL IS SUPPLEMENTED BY SPECIALISTS WHO CALL IN.
21	THEY'RE NOT SITTING MEMBERS. THEY DON'T VOTE THEIR
22	SCORES, BUT THEY DO PROVIDE OUTSIDE EXPERTISE AND
23	SPECIALIZED EXPERTISE. AS YOU POINT OUT, WHEN YOU
24	HAVE TWO PANELS BACK TO BACK, YOU CAN HAVE A GREATER
25	DISTRIBUTION OF EXPERTISE ON EACH PANEL RELATED TO

1	THE GRANTS THAT THEY'LL REVIEW.
2	CHAIRMAN TORRES: INCLUDING THE PATIENT
3	ADVOCATES WHO SERVE ON THOSE PANELS.
4	DR. TROUNSON: THERE ARE OTHER THINGS
5	WHICH IMPACT ON THAT. NO. 1, YOU'VE GOT TO EXPECT
6	THAT THE PATIENT ADVOCATES HAVE GOT TO GIVE UP QUITE
7	AN AMOUNT OF TIME, AND IT'S NOT THAT THEY GET
8	REALLY, IN MY VIEW, ADEQUATELY COMPENSATED FOR DOING
9	THAT. YOU HAVE TO GET THEM TO GIVE UP CONSIDERABLE
10	TIME AND THAT'S A DEMAND. YOU'VE ALSO THEN GOT TO
11	MULTIPLY THE NUMBER OF IN-HOUSE REVIEWS AND REPORTS
12	THAT YOU DO BY STAFF, AND THEN YOU'VE GOT TO LOOK AT
13	THE REVIEW PANEL. IF IT'S FOR THE ONE RFA, IT'S
14	VERY DIFFICULT TO COMPOSE THE REVIEWS BY EQUIVALENT
15	PEOPLE, PEOPLE WITH EQUIVALENT CAPACITY. SO YOU DO
16	GET A DIFFERENCE. YOU WILL ALWAYS GET A DIFFERENCE
17	ACROSS THOSE THINGS.
18	SO I THINK IT'S WE TRY TO BE MINDFUL OF
19	BEING ABLE TO KEEP IT WITHIN OUR ABILITIES TO DO IT
20	IN A WAY WHICH IS TIMELY, EFFECTIVE, AND EFFICIENT
21	AS POSSIBLE, BUT ALSO DOESN'T SORT OF STRIP THE TIME
22	OF A NUMBER OF OUR PEOPLE, INCLUDING THE IN-HOUSE
23	PEOPLE AND THE PATIENT ADVOCATES AND OTHERS THAT ARE
24	REQUIRED TO GIVE UP TIME FOR THE PROCESS.
25	CHAIRMAN TORRES: THANK YOU, MR.
	59
	5

	DARKISIERS REPORTING SERVICE
1	PRESIDENT. ANY COMMENTS, FURTHER COMMENTS IN
2	SACRAMENTO?
3	MR. JENSON: I FIND IT INTERESTING HERE
4	THAT THE ARGUMENTS ARE THAT A SMALLER GROUP IS MORE
5	EFFICIENT AND PROVIDES A HIGHER QUALITY PRODUCT IN
6	THE CASE OF THESE GRANT REVIEW GROUPS. HOWEVER,
7	THAT ARGUMENT DOESN'T SEEM TO BE APPLYING TO THE
8	29-MEMBER BOARD OF DIRECTORS.
9	CHAIRMAN TORRES: I ALWAYS THOUGHT WE
10	NEEDED A UNICAMERAL LEGISLATURE, BUT NO ONE WOULD
11	EVER LISTEN TO ME. ANY OTHER COMMENTS IN
12	SACRAMENTO? LA JOLLA?
13	MR. ROTH: NO.
14	CHAIRMAN TORRES: IRVINE?
15	DR. LEVIN: NO.
16	CHAIRMAN TORRES: PALO ALTO, WE'VE HEARD
17	FROM OUR CHAIRMAN. MOUNTAIN VIEW?
18	MR. GOLDBERG: NO.
19	CHAIRMAN TORRES: HEALDSBURG?
20	MS. SAMUELSON: I'D LIKE TO ECHO THE
21	COMMENTS OF MR. SHEEHY, MR. KLEIN, DR. TROUNSON.
22	THE PROCESS HAS BEEN WORKING QUITE WELL, I THINK.
23	I'D JUST LIKE TO RESPOND TO DAVE JENSON.
24	I THINK THEY ARE DIFFERENT SIZES BECAUSE THEY ARE
25	SERVING DIFFERENT PROCESSES AND OUTCOMES. THE
	60

1	WORKING GROUP IS DOING PEER REVIEW AND PROGRAMMATIC
2	REVIEW AND NEEDS AN ELABORATE DISCUSSION OF A VERY
3	COMPLICATED SUBJECT MATTER AND REAL GIVE-AND-TAKE
4	AND INVOLVEMENT BY THE WHOLE GROUP. AND IF THE
5	GROUP ITSELF WERE 50 PEOPLE, I THINK IT WOULD BE
6	IMPOSSIBLE TO REALLY BENEFIT FROM ALL OF THEIR
7	EXPERTISE. THE SIZE WE HAVE WORKS QUITE WELL, I
8	THINK.
9	I ALSO HAPPEN TO THINK THAT THE ICOC SIZE
10	WORKS WELL ALBEIT IT'S A DIFFICULT THING TO DO
11	BECAUSE WE WANT THE PARTICIPATION OF PEOPLE FROM
12	VERY DIVERSE BACKGROUNDS. AND I THINK THAT'S
13	ESSENTIAL TO THE PROCESS. I THINK THAT'S ONE VERY
14	IMPORTANT PIECE OF PROP 71, THE DEFINITION OF
15	BACKGROUND OF THE SEVERAL DIFFERENT KINDS OF
16	MEMBERS. AND I THINK THAT IT ADVANTAGES OUR PROCESS
17	TREMENDOUSLY.
18	CHAIRMAN TORRES: THANK YOU, JOAN.
19	COMMENTS FROM SAN FRANCISCO, PUBLIC OR OTHERWISE?
20	THERE BEING NONE, WE'LL MOVE TO ITEM 14. MR.
21	HARRISON.
22	MR. HARRISON: THIS IS A RECOMMENDATION
23	FROM THE LITTLE HOOVER COMMISSION THAT THE CITIZENS
24	FINANCIAL ACCOUNTABILITY OVERSIGHT COMMITTEE, WHICH
25	WAS ESTABLISHED AS PART OF PROP 71 AND WHICH IS
	C1

1	CHAIRED BY THE CONTROLLER AND WHICH CURRENTLY HAS
2	AUTHORITY TO REVIEW THE FINANCIAL PRACTICES OF CIRM,
3	ALSO BE AUTHORIZED TO CONDUCT A PERFORMANCE REVIEW
4	OF THE AGENCY.
5	CHAIRMAN TORRES: UNDER CURRENT LAW AND
6	PRACTICE, THE CIRM AGENCY IS SUBJECT TO YEARLY
7	INDEPENDENT FINANCIAL AUDITS. OUR CURRENT
8	CONTRACTOR IS MACIAS, GINI & O'CONNELL, MGO, WHO
9	PRESENTS ITS REPORT AS WELL TO THE CONTROLLER'S
10	COMMITTEE. THE STATE CONTROLLER HAS JURISDICTION
11	OVER US, AS INDICATED BY MR. HARRISON, FOR AN ANNUAL
12	AUDIT REVIEW OF THE INDEPENDENT FINANCIAL AUDIT
13	PERFORMED BY MGO, OUR PRIVATE PROVIDER. THE STATE
14	CONTROLLER'S OFFICE ALSO PERFORMS AN AUDIT REVIEW TO
15	DETERMINE WHETHER CIRM COMPLIED WITH THE
16	REQUIREMENTS OF PROP 71, AS WE'VE JUST HEARD, AS IT
17	RELATED TO CIRM'S CONFLICT OF INTEREST, GRANT
18	ADMINISTRATION, ADMINISTRATIVE EXPENSES AND
19	EXPENDITURES.
20	WE ALSO ARE SUBJECT, AND I HAVE ALL THESE
21	REPORTS HERE IN FRONT OF ME, AND THEY'RE QUITE
22	LENGTHY AND I'M SURE ALL OF US HAVE READ EVERY PAGE
23	OF THEM BECAUSE WE DID RESPOND TO THEM AS WELL. AND
24	THE BUREAU OF STATE AUDITS ALSO HAS JURISDICTION
25	OVER THIS AGENCY IN RESPECT TO ITS FINANCIAL

1	STABILITY AND REVIEW AS WELL AS ITS PERFORMANCE IN
2	TERMS OF ITS MISSION AND ITS GOALS.
3	THIS BOARD WILL REVIEW A STRATEGIC PLAN AT
4	OUR BOARD MEETING VERY SHORTLY IN A COUPLE OF WEEKS,
5	AGAIN ARTICULATING HOW SERIOUSLY WE TAKE THE
6	PERFORMANCE OF THIS AGENCY. I WILL ALSO ARGUE TO
7	MEMBERS OF THIS COMMITTEE THAT THE ASSEMBLY HEALTH
8	COMMITTEE, THE SENATE HEALTH COMMITTEE, THE BUDGET
9	SUBCOMMITTEES OF BOTH THE SENATE AND THE ASSEMBLY, I
10	HAVING BEEN CHAIR OF ONE WHEN I WAS IN THE WAYS AND
11	MEANS COMMITTEE, AS WELL AS THE LITTLE HOOVER
12	COMMISSION, AS WELL AS THE BIPARTISAN LEGISLATIVE
13	ANALYST ALL REVIEW EVERY STATE AGENCY, AND EVERY
14	STATE AGENCY IS REVIEWED IN TERMS OF ITS
15	APPLICABILITY, WHETHER OR NOT WE WISH TO BE. THE
16	JURISDICTION IS THEREIN FROM THE LEGISLATURE IN
17	REVIEWING OUR CAPACITY, OUR ADHERENCE TO MISSION,
18	ETC.
19	SO I THINK WHAT THE LITTLE HOOVER
20	COMMISSION IS RECOMMENDING HERE IS ALREADY TAKING
21	PLACE IN CALIFORNIA BY MORE THAN JUST ONE AGENCY AND
22	MORE THAN JUST BY THE EXECUTIVE BRANCH, BUT BY BOTH
23	HOUSES IN THE LEGISLATURE, AND CLEARLY BY THE
24	EXECUTIVE BRANCH AS WELL. COMMENTS IN SACRAMENTO?
25	DR. POMEROY: NONE.

1	CHAIRMAN TORRES: LA JOLLA?
2	MR. ROTH: NO.
3	CHAIRMAN TORRES: IRVINE?
4	DR. LEVIN: NO.
5	CHAIRMAN TORRES: PALO ALTO?
6	MR. KLEIN: WELL STATED.
7	CHAIRMAN TORRES: MOUNTAIN VIEW?
8	MR. GOLDBERG: NO.
9	CHAIRMAN TORRES: HEALDSBURG?
10	MS. SAMUELSON: I THINK WE SHOULD BE OPEN
11	TO ANY RESOURCES THAT CAN HELP US ACHIEVE OUR
12	MISSION FASTER AND MORE EFFECTIVELY. HAVING SAID
13	THAT, I DON'T SEE HOW THE CITIZENS FINANCIAL
14	ACCOUNTABILITY OVERSIGHT COMMITTEE COULD ASSIST US
15	WITH ACHIEVING OUR MISSION, WHICH IS ESSENTIALLY
16	WHAT I WOULD UNDERSTAND THE PERFORMANCE REVIEW TO BE
17	SEEKING, AS I WOULD UNDERSTAND IT. LET'S SAY WE
18	RAISE A \$1,000,000,000,000 AND WE THROW IT ALL OVER
19	THE PLACE, AND WE SURE CAN, DID WE SPEND OUR MONEY
20	WELL? THEY ARE NOT GOING TO BE IN A POSITION TO
21	ANSWER THAT QUESTION. AND I THINK THAT IS THE
22	POINT, AND SO I DON'T THINK THIS WOULD BE HELPFUL.
23	CHAIRMAN TORRES: ALL RIGHT. MOVING TO
24	SAN FRANCISCO. MR. SHEEHY.
25	MR. SHEEHY: THIS PROPOSAL I THINK IN A
	64

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	WAY KIND OF MISSES THE BOAT BECAUSE I DON'T REALLY
2	THINK I WOULD LIKE TO SEE US HAVE SOME SORT OF
3	PERFORMANCE AUDIT, BUT REALLY FROM A SCIENTIFIC
4	POINT OF VIEW. AND I THINK THAT I'M SURE THAT
5	THEY'RE THINKING ABOUT THIS INTERNALLY, BUT AT SOME
6	POINT WE ARE GOING TO HAVE TO GET A REALLY IN-DEPTH
7	LOOK AT WHERE WE'VE GONE, LOOK AT OUR STRATEGIC
8	PLAN, REALLY LOOK AT HOW CLOSE WE ARE TO MEETING THE
9	GOALS THAT WE MET, LOOK AT HOW THE SCIENCE HAS
10	CHANGED, DO SOME OF THE CONVENINGS THAT WE DID VERY
11	EARLY ON WHERE WE BRING IN I KNOW DR. HALL HAD
12	CONVENED THIS HUGE THREE-DAY WORKSHOP THAT BROUGHT
13	IN SCIENTISTS FROM AROUND THE WORLD. MAYBE WITH THE
14	ISSCR NEXT YEAR BEING IN SAN FRANCISCO.
15	BUT I THINK IT WOULD BE INTERESTING AT
16	SOME POINT TO KIND OF AUDIT THE STATE OF THE
17	SCIENCE, AUDIT WHAT WE'VE DONE, SEE HOW THEY MATCH
18	UP, LOOK AT OUR GOALS AS WE PROJECTED THEM. I THINK
19	THAT THIS SHOULD BE REALLY BOARD, STAFF, STRATEGIC
20	PLANNING, NOT SOMETHING THAT WE CAN KICK OUT TO THE
21	CFAOC. AND I THINK THIS SHOULD REALLY BE A HIGH
22	LEVEL SCIENTIFIC EXERCISE THAT REALLY LOOKS AND SEES
23	WHAT WE'VE DONE.
24	I WILL, THOUGH I DO HAVE TO GIVE KUDOS
25	TO STAFF. THE ANNUAL MEETING OF THE GRANTEES AND

1	THE REPORTS THAT COME FROM THAT IS A PRETTY GOOD
2	AUDIT OF WHAT WE'VE ACCOMPLISHED. WE ARE IN MANY
3	WAYS GETTING OUT THERE WHAT WE'VE ACHIEVED. THE
4	PRESIDENT'S REPORTS BEFORE EVERY MEETING BRING US UP
5	TO DATE ON THE SCIENCE AND WHAT SCIENCE WE HAVE BEEN
6	ABLE TO MOVE FORWARD WITH OUR FUNDING. BUT I THINK
7	THE IDEA THAT WE WOULD SYSTEMATICALLY ANALYZE WHERE
8	WE'VE BEEN AND WHERE WE WANT TO GO AND WHERE THE
9	SCIENCE IS AT SOME POINT IN THE NEXT COUPLE OF YEARS
10	IS ACTUALLY A GOOD IDEA. THIS PARTICULAR PROPOSAL
11	IS PROBABLY NOT HOW I WOULD DO IT.
12	CHAIRMAN TORRES: ANY OTHER COMMENTS
13	FROM DR. TROUNSON.
14	DR. TROUNSON: JUST TO ADD ON THAT WE'RE
15	REQUIRED TO ACTUALLY HAVE A SCIENTIFIC REVIEW WHICH
16	IS TIMED FOR NEXT YEAR. SO PERHAPS THE SECOND HALF
17	OF NEXT YEAR, WHICH WE WILL BRING A GROUP OF
18	SCIENTISTS, INTERNATIONAL SCIENTISTS, TO ADDRESS
19	THOSE ISSUES THAT YOU RAISED HERE. THAT'S REQUIRED
20	UNDER OUR ORIGINAL STRATEGIC PLAN.
21	CHAIRMAN TORRES: NO PUBLIC COMMENTS HERE.
22	IT'S MY UNDERSTANDING NOW, I DON'T KNOW HOW YOU ALL
23	HAVE DONE IT BEFORE, BUT IT'S MY UNDERSTANDING THAT
24	THE CHAIR WILL NOW ENTERTAIN A MOTION TO MAKE THESE
25	RECOMMENDATIONS TO THE BOARD SUBJECT TO THEIR

1	APPROVAL, SO THAT DOESN'T PRECLUDE ANY FURTHER
2	AMENDMENTS OTHER THAN WHAT WE'VE TALKED ABOUT TODAY
3	TO BE BROUGHT TO THE BOARD AS A WHOLE. AND I INTEND
4	TO MAKE THIS REPORT ON AUGUST 20TH TO THE FULL
5	BOARD, AND THEY'RE OBVIOUSLY SUBJECT TO ANY CHANGES
6	OR AMENDMENTS BEFORE WE DRAFT THE FINAL DOCUMENT
7	WITH THE APPROVAL OF THE BOARD THEN TO BE SENT AND
8	PRESENTED TO MEMBERS OF THE LEGISLATURE. IS THAT
9	OKAY WITH EVERYONE?
10	MR. KLEIN: IS IT MY UNDERSTANDING THAT
11	YOU'RE SEEKING A MOTION THAT WOULD
12	CHAIRMAN TORRES: ALLOW ME TO MAKE THESE
13	RECOMMENDATIONS TO THE FULL BOARD AUGUST 20TH.
14	MR. KLEIN: ENDORSING THOSE
15	RECOMMENDATIONS YOU'RE REFERRING TO WOULD BE
16	ENDORSING THE RECOMMENDATIONS FROM THE PRESIDENT AS
17	PRESENTED?
18	CHAIRMAN TORRES: RIGHT. WITH THE
19	INJECTION OF ANY COMMENTS THAT WERE MADE BY BOARD
20	MEMBERS. AND, OF COURSE, THOSE MEMBERS COULD MAKE
21	THOSE COMMENTS AS WERE ARTICULATED THROUGHOUT THIS
22	HEARING AT THE BOARD MEETING ON AUGUST 20TH WHEN I
23	PRESENT THE REPORT.
24	MR. ROTH: ART, IT'S DUANE ROTH. I WOULD
25	MAKE THAT MOTION.

1	CHAIRMAN TORRES: MOVED BY MR. ROTH.
2	SECONDED BY?
3	MR. KLEIN: I WILL SECOND IT.
4	CHAIRMAN TORRES: SECONDED BY MR. KLEIN.
5	DISCUSSION?
6	MR. ROTH: IN THE DISCUSSION, IN ADDITION
7	TO OUR COMMENTS THAT ARE GOING TO BE INCORPORATED IN
8	TODAY, I'D SUGGEST FOR THE BOARD, TO MAKE IT SIMPLE,
9	THAT WE INCLUDE THE LITTLE HOOVER RECOMMENDATION AND
10	THEN OUR RESPONSE, SO IT'S EASY TO FOLLOW.
11	CHAIRMAN TORRES: WELL PUT. ANY OTHER
12	COMMENTS ON OR DISCUSSION ON THE MOTION BEFORE US?
13	MR. KLEIN: AND I, AS THE SECOND ON THE
14	MOTION, IT'S MY UNDERSTANDING THAT MR. HARRISON'S
15	MEMO ON THE TWO ITEMS
16	CHAIRMAN TORRES: THAT IS CORRECT. THAT'S
17	WHY I SAID EVERYTHING THAT WE DISCUSSED TODAY WILL
18	BE INCLUDED AND INCORPORATED IN MY RECOMMENDATION,
19	OF COURSE, SUBJECT TO THE BOARD MEMBERS ARTICULATING
20	MORE RECOMMENDATIONS OR DIFFERENT APPROACHES AT THE
21	BOARD MEETING ITSELF.
22	MR. KLEIN: THANK YOU VERY MUCH.
23	CHAIRMAN TORRES: ANY OTHER COMMENTS?
24	PUBLIC COMMENTS?
25	MS. SAMUELSON: IT SEEMS TO ME THAT WE
	68

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	HAVE A CONSENSUS VIEW ABOUT EVERY ITEM, BUT I'M NOT
2	CERTAIN ABOUT THAT. I'M JUST INQUIRING.
3	CHAIRMAN TORRES: THAT WAS MY FEELING.
4	MS. SAMUELSON: SO WE DON'T NEED A FORMAL
5	VOTE BECAUSE IT DOES SEEM THAT THAT WOULD BE MORE
6	EFFECTIVE THAN JUST IF WE DIDN'T HAVE TO VOTE.
7	CHAIRMAN TORRES: MR. HARRISON.
8	MR. HARRISON: AS I UNDERSTAND IT, A
9	MOTION HAS BEEN MADE, SO WE WILL INDEED TAKE A ROLL
10	CALL VOTE. IF I COULD JUST TRY TO RESTATE THE
11	MOTION TO MAKE SURE IT'S CLEAR TO EVERYONE. THE
12	MOTION WOULD BE TO RECOMMENDED THE BOARD ACCEPT THE
13	STAFF RECOMMENDATIONS DESCRIBED TODAY ON WHAT ARE
14	IDENTIFIED AS ITEMS 6 THROUGH 14 IN THE JUNE 30,
15	2009, MEMO FROM BOB KLEIN AND ART TORRES TO THE
16	BOARD. THEY WOULD RECOMMEND THOSE POSITIONS TO THE
17	ICOC AT THE MEETING ON THE 20TH.
18	CHAIRMAN TORRES: INCLUDING THE MEMOS THAT
19	WE RECEIVED FROM YOU AS PER MR. KLEIN.
20	MR. HARRISON: CORRECT.
21	MR. KLEIN: AS A QUESTION, IT'S MY
22	UNDERSTANDING THAT SINCE WE'RE FORWARDING A MOTION
23	TO THE BOARD, WOULD THERE BE WAS THE VOTE AT THE
24	LAST MEETING OF THIS COMMITTEE ON ITEMS 1 THROUGH 5,
25	WAS THAT AN INTERIM VOTE, OR SHOULD THAT ALSO BE

1	IF IT WAS AN INTERIM VOTE
2	CHAIRMAN TORRES: NO, IT'S NOT AN INTERIM
3	VOTE. IT WAS A VOTE THAT WAS DONE IN RESPONSE TO
4	THE CONSTITUTIONAL ISSUES, WHICH WAS A SEPARATE
5	ITEM, AND I WILL REPORT TO THE BOARD THAT WAS THE
6	CASE AS I DID AT THE OUTSET OF THIS HEARING.
7	MR. KLEIN: THANK YOU VERY MUCH.
8	MS. SAMUELSON: DID THE STAFF
9	RECOMMENDATIONS IN EVERY CASE ECHO THE CONSENSUS
10	VIEW OF THE LEGISLATIVE SUBCOMMITTEE MEMBERS?
11	CHAIRMAN TORRES: YES. ALL RIGHT. WE'RE
12	READY FOR A VOTE?
13	DR. POMEROY: I HAVE A QUESTION ABOUT
14	THAT. IS THE MOTION TO HAVE YOU, ART, SUMMARIZE THE
15	RECOMMENDATIONS AND DISCUSSION OR JUST TO PRESENT
16	THE STAFF RECOMMENDATIONS? I'M SOMEWHAT CONFUSED.
17	CHAIRMAN TORRES: MY INTENT IS TO PRESENT
18	THE RECOMMENDATIONS THAT WE HAVE RECEIVED A
19	CONSENSUS ON, INCLUDING THE DOCUMENTS THAT WERE
20	REFERENCED AND I BELIEVE EACH OF US HAVE A COPY BY
21	MR. HARRISON, AND ALSO AT THAT POINT I THINK IT'S
22	INCUMBENT UPON MEMBERS OF THE LEGISLATIVE COMMITTEE
23	TO ADD THEIR COMMENTS TO THAT DISCUSSION.
24	DR. POMEROY: SO YOU'LL PREPARE, IN
25	ESSENCE, A SUMMARY OF WHAT'S HAPPENED TODAY AND

1	PRESENT THAT.
2	CHAIRMAN TORRES: THAT IS CORRECT. THAT'S
3	MY INTENT SUBJECT TO APPROVAL BY THE BOARD. SO THIS
4	IS A VOTE OF OUR SUBCOMMITTEE TO THE BOARD THAT WE
5	HAVE A CONSENSUS ON THESE ISSUES, BUT THAT DOESN'T
6	PRECLUDE THAT CONSENSUS BEING CHANGED AT THE BOARD
7	MEETING. ALL RIGHT. I'M GOING TO CALL FOR THE
8	ROLL.
9	MS. KING: JACOB LEVIN.
10	DR. LEVIN: YES.
11	MS. KING: MICHAEL GOLDBERG.
12	MR. GOLDBERG: YES.
13	MS. KING: BOB KLEIN.
14	MR. KLEIN: YES.
15	MS. KING: CLAIRE POMEROY.
16	DR. POMEROY: YES.
17	MS. KING: FRANCISCO PRIETO.
18	DR. PRIETO: YES.
19	MS. KING: DUANE ROTH.
20	MR. ROTH: YES.
21	MS. KING: JOAN SAMUELSON.
22	MS. SAMUELSON: YES.
23	MS. KING: JEFF SHEEHY.
24	MR. SHEEHY: YES.
25	MS. KING: ART TORRES.
	71

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN TORRES: YES.
2	MS. KING: AND THAT MOTION CARRIES WITH
3	NINE YES VOTES AND NO OTHER VOTES.
4	CHAIRMAN TORRES: NINE YES VOTES AND NO
5	OTHER VOTES. THE MOTION CARRIES.
6	ALL RIGHT. WE'LL MOVE TO THE SECOND ITEM
7	AND OUR LAST ITEM ON OUR AGENDA, WHICH IS SOMETHING
8	WE APPROVED TO BE PUT ON THE AGENDA AT OUR LAST
9	LEGISLATIVE SUBCOMMITTEE AT THE REQUEST OF MR.
10	SHEEHY AND MYSELF, WHICH IS CONSIDERATION OF
11	ENDORSEMENT OF THE PUBLIC HEALTHCARE OPTION AS PART
12	OF THE NATIONAL HEALTHCARE LEGISLATION CURRENTLY
13	UNDER CONSIDERATION BY THE U.S. CONGRESS.
14	I WANTED TO MAKE SURE THAT EACH OF THE
15	MEMBERS OF THE COMMITTEE RECEIVED BOTH A REVIEW OF
16	THOSE POSITIONS IN SUPPORT OF THIS OPTION AS WELL AS
17	THOSE POSITIONS IN OPPOSITION TO THIS OPTION. AND
18	YOU HAVE A DOCUMENT CALLED AGENDA ITEM NO. 4,
19	DOCUMENTS, TWO ARTICLES IN FAVOR OF PUBLIC OPTION
20	AND THREE ARTICLES IN OPPOSITION, AS WELL AS THE
21	CONGRESSIONAL BUDGET OFFICE MATERIALS, AS WELL AS
22	THE HEALTHCARE LEGISLATION OVERVIEW THAT WE PROVIDED
23	YOU, AS WELL AS SOME OF THE SUMMARIZING SOME OF
24	THE COMMENTS FOLKS HAVE MADE ON THIS ISSUE. I NOW
25	TURN THE FLOOR TO MR. SHEEHY.
	72
	<i>1 </i>

1	MR. SHEEHY: YES. I THOUGHT THAT THIS
2	I WOULDN'T HAVE WADED INTO THIS BILL EXCEPT WE'VE
3	ALREADY TAKEN A POSITION ON ONE ITEM WITHIN THE
4	HEALTHCARE REFORM ACT. AND I WOULD NOTE THAT ACCESS
5	TO THERAPY HAS BEEN AN ISSUE THAT WE'VE DEALT WITH
6	IN THE IP TASK FORCE EXTENSIVELY BOTH FOR
7	NOT-FOR-PROFIT AND FOR-PROFIT FIRMS AND THAT,
8	FRANKLY, SUCCESSFUL HEALTHCARE REFORM ACT PASSAGE
9	WOULD ELIMINATE ONE OF THE BIGGEST PERCEIVED
10	OBSTACLES BY INDUSTRY PARTICIPATING WITH US, WHICH
11	IS THE NEED TO HAVE ACCESS PLANS FOR UNINSURED
12	CALIFORNIANS.
13	SO IF THE HEALTHCARE REFORM ACT DOES PASS
14	AND DOES INDEED COVER 97 PERCENT OF ALL AMERICANS,
15	WHICH I THINK IS ONE OF THE MORE FAVORED BILLS WE
16	DO, WE WOULD GREATLY DIMINISH THE NEED FOR HAVING TO
17	MAKE SPECIAL ARRANGEMENTS TO MAKE SURE THAT
18	CALIFORNIANS GET ACCESS TO THERAPIES THAT THEY'RE
19	PAYING TO DEVELOP.
20	SO THOSE ARE THE TWO REASONS THAT I
21	THOUGHT IT WAS OKAY TO WADE INTO THIS. THE SPECIFIC
22	ISSUE IN FRONT OF US IS TO ENDORSE A PUBLIC
23	INSURANCE OPTION WITHIN THE HEALTHCARE REFORM ACT.
24	AND THIS WOULD BE AN INSURANCE OPTION THAT WOULD BE
25	RUN BY THE SECRETARY OF HEALTH AND HUMAN SERVICES

1	THROUGH THE DEPARTMENT OF HEALTH AND HUMAN SERVICE
2	AND WOULD PROVIDE INSURANCE THAT WOULD CREATE A
3	BASELINE INSURANCE PLAN THAT PEOPLE WITHOUT
4	INSURANCE OR COMPANIES THAT WEREN'T PROVIDING
5	INSURANCE COULD ACCESS AMONGST ALL THE OTHER PLANS
6	THAT ARE GOING TO BE PUT INTO THIS POTENTIAL
7	INSURANCE POOL THAT WOULD ALLOW SUBSIDIZED PURCHASE.
8	THE PUBLIC PLAN PLAYS A VERY IMPORTANT
9	ROLE IN THAT IT SETS A BASELINE SO THAT NO ONE CAN
10	BE DENIED COVERAGE FOR PREEXISTING CONDITIONS, FOR
11	INSTANCE, THAT PREMIUMS DO NOT GET SO EXCESSIVE THAT
12	PEOPLE CAN'T AFFORD TO PAY THEM AND MAINTAIN
13	COVERAGE. BUT THERE AREN'T THESE RESCISSIONS WHICH
14	WE SEE SO MUCH OF WHERE SOMEONE FAILS TO REPORT
15	SOMETHING IN THEIR HEALTHCARE WHEN THEY FIRST ENROLL
16	WITH THE COMPANY AND THEN THEY HAVE A PROBLEM DOWN
17	THE LINE AND SUDDENLY THEIR HEALTHCARE IS JERKED
18	RIGHT OUT FROM UNDER THEM WHEN THEY MOST NEED IT.
19	SO THE IDEA BETWEEN A PUBLIC INSURANCE
20	OPTION IS TO PROVIDE AN INSURANCE OPTION THROUGH THE
21	FEDERAL GOVERNMENT THAT WILL PROVIDE A BASELINE
22	COVERAGE FOR ALL AMERICANS. NOW, THERE'S SOME
23	ISSUES WITHIN IT THAT ARE DEBATABLE. I THINK MOST
24	OF US WOULD BE SUPPORTIVE OF A PLAN THAT IS NOT
25	UNDULY SUBSIDIZED BY THE FEDERAL GOVERNMENT THAT

	-
1	COMPETES UNFAIRLY, EVEN PLAYING FIELD.
2	THERE IS SOME DEBATE ON THE ISSUE OF
3	WHETHER THEY WOULD PURCHASE WOULD NEGOTIATE
4	PURCHASING ARRANGEMENTS WITH MEDICARE. I PERSONALLY
5	WOULD HAVE SUPPORTED PURCHASING WITH MEDICARE, BUT
6	I'M ALSO VERY COMFORTABLE WITH THE COMPROMISE THAT
7	WAS WORKED OUT IN HOUSE COMMERCE, SCIENCE &
8	TECHNOLOGY WHERE THEY DIRECT THE SECRETARY TO
9	NEGOTIATE SEPARATELY. I THINK A LOT OF THE DOCTORS
10	GROUPS IN THE COUNTRY ARE MORE SUPPORTIVE OF THAT
11	OPTION.
12	BUT I WOULD HOPE THAT WE AS A BOARD COULD
13	SUPPORT A STRONG PUBLIC INSURANCE OPTION AS PART OF
14	THE HEALTHCARE REFORM ACT GOING FORWARD.
15	CHAIRMAN TORRES: IS THAT A MOTION, MR.
16	SHEEHY?
17	MR. SHEEHY: THAT IS A MOTION.
18	CHAIRMAN TORRES: SO MOVED BY MR. SHEEHY.
19	IS THERE A SECOND?
20	DR. PRIETO: SECOND.
21	CHAIRMAN TORRES: DISCUSSION? WHO WAS THE
22	SECOND? DR. PRIETO SECONDS MR. SHEEHY'S MOTION.
23	ALL RIGHT.
24	MR. KLEIN: ASK MR. SHEEHY A QUESTION.
25	SO, JEFF, YOU AND I HAVE DISCUSSED THE FACT THAT TO
	75
	• •

1	HAVE REAL ACCESS TO A PROGRAM FOR A PUBLIC OPTION,
2	IT IS VERY IMPORTANT TO HAVE HIGH RATES OF
3	PARTICIPATION BY PHYSICIANS IN THIS COUNTRY. AND IN
4	THE HOUSE THERE WAS A COMPROMISE WHERE THEY
5	SPECIFICALLY AGREED TO INCREASE PHYSICIAN
6	REIMBURSEMENT RATES AND HOSPITAL REIMBURSEMENT RATES
7	ABOVE THE MEDICARE LEVEL TO MAKE CERTAIN THAT THERE
8	WAS ADEQUATE PATIENT LEVEL AND THAT, IN FACT, WE
9	WEREN'T OVERBURDENING AN ALREADY TROUBLED FINANCIAL
10	SYSTEM FOR HOSPITALS AND PHYSICIANS WHO ARE BEING
11	PUSHED OUT OF SERVING THE PEOPLE IN GREATEST NEED IN
12	THIS COUNTRY.
13	SO IN YOUR MOTION WOULD YOU BE WILLING TO
14	SAY THAT THE MOTION WOULD INCLUDE REIMBURSEMENT
15	RATES THAT WERE SIGNIFICANT IMPROVEMENTS ON MEDICARE
16	TO ENHANCE THE LEVELS OF PARTICIPATION OF PHYSICIANS
17	AND TO MAKE IT MORE ECONOMICALLY FEASIBLE FOR
18	HOSPITALS TO HAVE A BROADER PARTICIPATION?
19	MR. SHEEHY: MAYBE THE BEST WAY AND MAYBE
20	THIS WILL MAKE YOU COMFORTABLE IF WE PERHAPS TIE IT
21	TO THAT SPECIFIC BILL.
22	MR. KLEIN: THAT WOULD BE FINE.
23	MR. SHEEHY: LET'S SET THAT AS THE
24	BASELINE. OBVIOUSLY THINGS ARE GOING TO CHANGE, BUT
25	I THINK AT LEAST FOR THE HOUSE THAT THIS IS GOING TO
	76
	, v

1	BE FAIRLY DEFINITIVE AND SEEMS TO BE A PRETTY STRONG
2	COMPROMISE. WE MAY SEE SOMETHING DIFFERENT FROM THE
3	SENATE, BUT AT THIS POINT IF WE WANT TO REFERENCE
4	THAT PARTICULAR BILL THAT'S PASSED THROUGH THE HOUSE
5	COMMERCE, SCIENCE & TECHNOLOGY, I THINK WHAT WOULD
6	ACCOMPLISH WHAT YOU WANT TO DO, AND I WOULD BE VERY
7	COMFORTABLE WITH ACCEPTING THAT AS A FRIENDLY
8	AMENDMENT.
9	CHAIRMAN TORRES: ALL RIGHT. SO MOVED.
10	DISCUSSION FROM SACRAMENTO?
11	DR. POMEROY: NO COMMENT.
12	CHAIRMAN TORRES: LA JOLLA?
13	MR. ROTH: SO, YOU KNOW, I SHARE THE
14	PRINCIPLES OF WHAT JEFF JUST WENT THROUGH, BUT I
15	DON'T UNDERSTAND QUITE WHY THE PUBLIC OPTION HAS TO
16	BE PART OF THAT. AND I'LL TELL YOU MY BIAS HERE IS
17	HAVING TO DEAL WITH FOREIGN COUNTRIES THAT HAVE ONLY
18	A PUBLIC OPTION. THAT'S WHERE ACCESS GETS REALLY
19	CONFOUNDED, AND PRODUCTS ARE WITHHELD BECAUSE OF
20	REQUESTS FOR ADDITIONAL STUDIES THAT TAKE TWO TO
21	THREE YEARS LONGER. THEY'RE WITHHELD BECAUSE THEY
22	DON'T BELIEVE COST BENEFIT HAS BEEN DEMONSTRATED.
23	SO I THINK THERE ARE SOME PROS AND CONS TO
24	THAT. WHILE I DON'T WANT TO GET INTO THE POLITICS
25	OF IT, I'M NOT SURE WHY THE PRINCIPLES THAT WERE
	77
	• •

1	EXPRESSED BY JEFF SHOULDN'T BE WHAT THIS GROUP WOULD
2	RECOMMEND, ACCESS, THE PORTABILITY OF INSURANCE, THE
3	NONDENIALS AND THINGS LIKE THAT, WITHOUT HAVING TO
4	SPECIFICALLY SAY PUBLIC ACCESS PLAN, WHICH I THINK
5	IS ONLY POTENTIALLY A PART OF THAT. BUT THE REST OF
6	THIS I THINK WE COULD ALL AGREE ON.
7	THOSE ARE MY THOUGHTS, THAT I WOULD NOT BE
8	IN FAVOR OF JUST SINGLING OUT AND SAYING THAT WE
9	SUPPORT A PUBLIC OPTION. I WOULD SUPPORT THE
10	PRINCIPLES OF WHAT WE THINK SHOULD BE IN ANY
11	HEALTHCARE PACKAGE.
12	MR. SHEEHY: I GUESS I JUST COME BACK TO
13	THE DISCUSSION WE HAD AROUND BIOSIMILARS. WE WENT
14	DOWN THE SAME ROAD, AND WE DECIDED THAT IT WAS
15	IMPORTANT TO SUPPORT A SPECIFIC BILL RATHER THAN
16	PRINCIPLES, THAT WE WOULD NOT BE LISTENED TO IF WE
17	DID NOT SUPPORT A SPECIFIC BILL. AND I WOULD NOTE.
18	I DO THINK IT'S RATHER DISINGENUOUS. I'M NOT
19	ACCUSING YOU OF THIS, MR. ROTH, BUT SOME OPPONENTS
20	OF THE PUBLIC INSURANCE OPTION IMMEDIATELY ANALOGIZE
21	THAT TO SINGLE PAYER SYSTEMS.
22	THIS IS JUST ONE OPTION OF MANY OPTIONS
23	THAT WILL BE AVAILABLE TO PEOPLE, INCLUDING PRIVATE
24	HEALTHPLANS, PRIVATELY OFFERED INSURANCE PLANS. SO
25	TO SUDDENLY CONFLATE A PUBLIC OPTION, WHICH THE CBO
	78
	, ,

1	DOESN'T ANTICIPATE BEING TAKEN UP BY MORE THAN 10
2	PERCENT OF THE POPULATION, TO SUDDENLY BEING SINGLE
3	PAYER AND THEN BRINGING ALL THE PROBLEMS THAT PEOPLE
4	PERCEIVE ABOUT SINGLE PAYER SYSTEMS INTO THIS
5	DISCUSSION IS NOT REALLY A FAIR ARGUMENT.
6	AND WE ONLY HAVE TO NOTE SOME OF THE
7	ABUSES OF THE INSURANCE COMPANIES. I MEAN IT IS A
8	FACT THAT ON CERTAIN PROCEDURES, AND I HAVE SEEN
9	THIS WITH PEOPLE WITH HIV WHERE THE COMPANIES HAVE
10	SET UP POLICIES WITH AUTOMATIC DENIAL FOR ACCESS TO
11	CERTAIN THERAPIES, AND THAT THEY RECOGNIZE AT THE
12	END OF THE DAY A CERTAIN NUMBER OF PEOPLE WILL HAVE
13	DIED OR PROGRESSED TO A POINT WHERE THEY NO LONGER
14	NEED THE THERAPY. CERTAIN AMOUNT OF PEOPLE WILL
15	HAVE GIVEN UP APPEALING THE DENIAL AND THEIR
16	PHYSICIANS INDIVIDUAL PATIENTS OR THEIR
17	PHYSICIANS OR, YOU KNOW, SOME SMALL SUBSET WILL
18	ACTUALLY GET THE THERAPY THAT THEY NEED TO SUCCEED
19	IN MAINTAINING THEIR HEALTH OR ATTAINING HEALTH
20	THROUGH ENORMOUS AMOUNTS OF EFFORT, THROUGH ENORMOUS
21	AMOUNTS OF WORK. AND THE COMPANY HAS DONE COST
22	BENEFIT ANALYSIS TO KIND OF COME UP WITH THE FACT
23	THAT THIS DENIAL THIS GRUDGING THIS DENIAL AND
24	GRUDGING PROVISION OF BENEFITS THAT THEY'RE LEGALLY
25	OBLIGATED TO PROVIDE, THAT THIS ACTUALLY, EVEN WITH
	79

1	LITIGATION COST BUILT IN, COMES TO MAKE MORE MONEY
2	FOR THEM THAN ACTUALLY PROVIDING THE BENEFITS
3	THEY'RE SUPPOSED TO PROVIDE.
4	SO IT'S NOT AS IF THE INSURANCE COMPANIES
5	HAVE BEEN GOOD PLAYERS IN THIS BOTH THROUGH THE
6	RESCISSIONS, THROUGH THE DENIAL, THROUGH PREEXISTING
7	CONDITIONS, ETC., ETC. SO I THINK A PUBLIC OPTION
8	THAT WE LOOK AT BEING TAKEN UP PROBABLY, IF WE TAKE
9	THE CBO ESTIMATES, BY ABOUT 10 PERCENT OF AMERICANS
10	IS A GOOD WAY TO MAKE SURE THAT WE HAVE A FAIR
11	PLAYING FIELD AND THAT INDUSTRY IS THAT THE
12	INSURANCE INDUSTRY IS HELD ACCOUNTABLE AND THAT
13	THERE'S AT LEAST ONE PLAYER IN THE GAME WHO'S
14	SETTING A BASELINE.
15	SO I THINK THIS IS RELATIVELY I THINK
16	THIS WOULD BE VERY GOOD TO GO FORWARD WITH IN FACT.
17	DR. PRIETO: I'D ALSO LIKE TO RESPOND TO
18	DUANE'S COMMENTS. I PRACTICED MEDICINE FOR THE LAST
19	25 YEARS UNDER OUR DOMINANT PRIVATE OPTION. AND
20	MANY OF THE REFORMS THAT HAVE BEEN PROMISED NOW OR
21	SUGGESTED BY THOSE WHO ARE OPPOSING A PUBLIC OPTION
22	ALSO CAME UP THE LAST TIME THAT HEALTHCARE REFORM
23	WAS ON THE NATIONAL AGENDA. AS SOON AS THAT EFFORT
24	IN THE EARLY '90S WAS DEFEATED, ALL OF THOSE REFORMS
25	SIMPLY WENT AWAY.

1	SO I THINK I HAVE VERY LITTLE CONFIDENCE
2	WITHOUT A PUBLIC GUARANTEED OPTION AVAILABLE TO
3	PEOPLE THAT WE WILL HAVE THESE ABUSES AND THEY ARE
4	ABUSES REMOVED FROM OUR SYSTEM. IT IS NOT A
5	PUBLIC OPTION DOES NOT MEAN THE END OF PRIVATE
6	INSURANCE. AND, IN FACT, VIRTUALLY ALL OF THE OTHER
7	COUNTRIES THAT HAVE PUBLIC INSURANCE SYSTEMS ALSO
8	MAINTAIN PRIVATE INSURANCE SYSTEMS IN ONE FORM OR
9	ANOTHER, AND THAT VARIES CONSIDERABLY. IF YOU GO TO
10	GERMANY, IF YOU GO TO FRANCE, EVEN IF YOU GO TO
11	ENGLAND, THE MOST SOCIALIZED SYSTEM OF ALL, THERE
12	ARE PRIVATE INSURANCE COMPANIES THAT CONTINUE TO
13	OPERATE AND PROVIDE THEIR SERVICES, BUT THEY DO IT
14	WITHIN A FRAMEWORK WHERE THE GOLD STANDARD IS SET BY
15	THE PUBLIC OPTION. AND THAT'S SOMETHING THAT CANNOT
16	BE TAKEN AWAY FROM THEIR CITIZENS. I THINK WE
17	DESERVE THE SAME.
18	CHAIRMAN TORRES: THANK YOU, DR. PRIETO.
19	ANY OTHER COMMENTS FROM SACRAMENTO? LA JOLLA?
20	DUANE, DID YOU WANT TO ADD ANYTHING?
21	MR. ROTH: NO. THAT'S FINE.
22	CHAIRMAN TORRES: IRVINE?
23	DR. LEVIN: NO.
24	CHAIRMAN TORRES: PALO ALTO?
25	MR. KLEIN: NO.
	81
	01

1	CHAIRMAN TORRES: MOUNTAIN VIEW?
2	MR. GOLDBERG: I THINK WE SHOULDN'T WEIGH
3	IN ON THIS PERSONALLY.
4	CHAIRMAN TORRES: THANK YOU, MR. GOLDBERG.
5	HOW YOU DOING, MICHAEL?
6	MR. GOLDBERG: VERY WELL THANK YOU. I
7	HAVE TREMENDOUS RESPECT FOR THE OPINIONS OF MY OTHER
8	COLLEAGUES.
9	CHAIRMAN TORRES: JOAN SAMUELSON IN
10	HEALDSBURG?
11	MS. SAMUELSON: I AGREE WITH MICHAEL. I'M
12	FOLLOWING THIS CLOSELY AND CARE A GREAT DEAL ABOUT
13	IT, BUT I DON'T FEEL EXPERT ENOUGH AT THIS POINT TO
14	WEIGH IN. IT'S AT LEAST PREMATURE ON MY PART, AND
15	I'M NOT SURE THAT THAT LEGISLATION IS CLOSE ENOUGH
16	TO WHAT WE NEED TO BE FOLLOWING FOR OUR SPECIFIC
17	MISSION. IT MAY BE, BUT THE IMPACT IT MAY HAVE MAY
18	NOT BE KNOWN FOR A VERY LONG TIME TO SEE IF IT WORKS
19	OR NOT, AMONG OTHER QUESTIONS. I'D RATHER WE WAIT.
20	DR. PRIETO: I'D LIKE TO RESPOND TO JOAN
21	BECAUSE I'VE THOUGHT ABOUT THIS A LOT ALSO FROM THE
22	PERSPECTIVE OF BEING A PATIENT ADVOCATE. AND ALL
23	THE DISCUSSIONS WE HAD IN THE IP TASK FORCE ABOUT
24	ACCESS AND AFFORDABILITY, AND I CERTAINLY ARGUED FOR
25	AND SUPPORTED THE POSITIONS WE ENDED UP TAKING THAT

1	GUARANTEED THAT ANYONE BRINGING THE FRUITS OF THEIR
2	CIRM-FUNDED RESEARCH TO MARKET HAD TO HAVE AN ACCESS
3	PLAN. BUT EVEN IF WE HAD A HOME RAN, A GRAND SLAM,
4	IF WE CURE CANCER WITH CIRM-FUNDED RESEARCH AND MAKE
5	THAT AVAILABLE AT A DOLLAR A POP TO EVERYONE IN
6	CALIFORNIA, WE WILL HAVE DONE NOTHING FOR PEOPLE
7	WITH DIABETES, WITH PARKINSON'S, WITH MS, WITH
8	ALZHEIMER'S, ANY OTHER CHRONIC DISEASE. AND THE
9	ONLY WAY YOU ADDRESS ALL OF THIS IS WITH AN
10	INCLUSIVE SYSTEM, AND WE ALSO THEN REMOVE THAT
11	BARRIER THAT JEFF REFERRED TO THAT ANY DISINCENTIVE
12	OF PRIVATE COMPANIES TO PARTICIPATE IN OUR PROGRAM,
13	AND WE WANT TO REMOVE THOSE BARRIERS.
14	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER
14 15	CHAIRMAN TORRES: ALL RIGHT. ANY OTHER COMMENTS FROM SACRAMENTO?
15	COMMENTS FROM SACRAMENTO?
15 16	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE
15 16 17	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE
15 16 17 18	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE
15 16 17 18 19	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE DISCOVERIES FOR ALL, AND THAT INCLUDES EQUAL ACCESS.
15 16 17 18 19	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE DISCOVERIES FOR ALL, AND THAT INCLUDES EQUAL ACCESS. AND THAT WAS THE REASON I ACTUALLY SUPPORTED THE
15 16 17 18 19 20	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE DISCOVERIES FOR ALL, AND THAT INCLUDES EQUAL ACCESS. AND THAT WAS THE REASON I ACTUALLY SUPPORTED THE MOTION THAT WE MADE ON THE BIOSIMILARS BECAUSE I
15 16 17 18 19 20 21	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE DISCOVERIES FOR ALL, AND THAT INCLUDES EQUAL ACCESS. AND THAT WAS THE REASON I ACTUALLY SUPPORTED THE MOTION THAT WE MADE ON THE BIOSIMILARS BECAUSE I THINK IT REALLY IS IMPERATIVE THAT WE LINK OUR
15 16 17 18 19 20 21 22	COMMENTS FROM SACRAMENTO? DR. POMEROY: WE'VE HAD DISCUSSIONS HERE ABOUT WHAT OUR ROLE IS, AND WE DECIDED THAT OUR ROLE IS TO MAKE SURE THAT THERE WILL BE ACCESS TO THESE DISCOVERIES FOR ALL, AND THAT INCLUDES EQUAL ACCESS. AND THAT WAS THE REASON I ACTUALLY SUPPORTED THE MOTION THAT WE MADE ON THE BIOSIMILARS BECAUSE I THINK IT REALLY IS IMPERATIVE THAT WE LINK OUR SCIENCE TO POLICY. I THINK THAT, UNLIKE DR. PRIETO,

1	BECAUSE WE HAVE MANY PUBLIC OPTIONS IN THIS COUNTRY
2	ALREADY. WE HAVE MEDICARE. WE HAVE MEDI-CAL. AND
3	I THINK THAT IT IS IMPERATIVE THAT WE NOT DEFINE
4	CERTAIN CLASSES OF PEOPLE WHO HAVE THE ACCESS TO
5	BASIC HEALTHCARE.
6	SO A PUBLIC OPTION THAT GIVES THOSE PEOPLE
7	WHO FALL BETWEEN THE CRACKS OF MEDICARE AND MEDI-CAL
8	AND HEALTHY FAMILIES, ETC., PICKS UP THOSE FEW
9	REMAINING PEOPLE IS CONSISTENT WITH OUR MISSION OF
10	ENSURING ACCESS TO THE DISCOVERIES THAT WE MAKE, SO
11	I WILL BE VOTING IN FAVOR OF THE MOTION.
12	CHAIRMAN TORRES: WELL SAID, DR. POMEROY.
13	ANY OTHER COMMENTS IN SACRAMENTO? ALL RIGHT.
14	IRVINE?
15	DR. LEVIN: NO.
16	CHAIRMAN TORRES: PALO ALTO I THINK WE'VE
17	HEARD. MOUNTAIN VIEW WE'VE HEARD. AND NOW SAN
18	FRANCISCO, ANY PUBLIC COMMENT? MR. REED.
19	MR. REED: FIRST OFF, I THINK THAT THIS IS
20	NOT AN EXTREME POSITION, BUT THIS IS A MIDDLE
21	POSITION. A SINGLE PAYER WOULD BE ONE EXTREME,
22	TOTAL PRIVATE THE OTHER EXTREME. THIS IS THE
23	MIDDLE. THIS IS JUST AN OPTION. IT GIVES US A
24	CHOICE, WHICH MOST PEOPLE IN AMERICA ARE IN FAVOR OF
25	CHOICE.
	84
	UT

1	ALSO I'D ECHO DR. POMEROY'S COMMENTS.
2	AGAIN AND AGAIN WHEN I HEAR ABOUT THE ACCESS AND
3	NEED FOR THIS, WE ARE NOT JUST FOR CURE. WE'RE ALSO
4	FOR CARE. THIS COMBINES BOTH. THIS IS WHAT DRIVES
5	US ALL. I THINK THIS IS AN EXCELLENT THING AND WE
6	SHOULD BE PART OF IT.
7	CHAIRMAN TORRES: ALL RIGHT. NO FURTHER
8	DISCUSSION, THE CHAIR DR. TROUNSON.
9	DR. TROUNSON: JUST A COMMENT BECAUSE I'VE
10	LIVED UNDER TWO SYSTEMS, THE AMERICAN SYSTEM FOR THE
11	LAST TWO YEARS AND A SYSTEM WHICH OFFERED EVERYBODY
12	PUBLIC HEALTH SYSTEM THAT YOU COULD THEN CHOOSE
13	PRIVATE HEALTH INSURANCE TO GIVE YOU A BROADER
14	CHOICE AND MORE SPECIALIZED CHOICE. YOU COULD
15	CHOOSE YOUR DOCTOR AND HOSPITAL AS A PRIVATE
16	HOSPITAL. YOU COULD MAKE CHOICES, BUT EVERYBODY IN
17	THE WHOLE COMMUNITY WAS COVERED AND COVERED VERY
18	ADEQUATELY.
19	HAVING LIVED IN THE TWO SYSTEMS, I DO HOPE
20	YOU CHOOSE A SYSTEM LIKE AUSTRALIA.
21	CHAIRMAN TORRES: I HOPE YOU FILED YOUR
22	CONFLICT OF INTEREST STATEMENT ON THAT. ALL RIGHT.
23	LET THE RECORD SHOW THAT AUSTRALIA SHOULD RULE HERE.
24	ALL RIGHT. THE MOTION IS BEFORE US. WE'LL CALL THE
25	ROLL.

1	MS. KING: JACOB LEVIN.
2	DR. LEVIN: YES.
3	MS. KING: MICHAEL GOLDBERG.
4	MR. GOLDBERG: NO.
5	MS. KING: BOB KLEIN.
6	MR. KLEIN: YES.
7	MS. KING: CLAIRE POMEROY.
8	DR. POMEROY: YES.
9	MS. KING: FRANCISCO PRIETO.
10	DR. PRIETO: YES.
11	MS. KING: DUANE ROTH.
12	MR. ROTH: NO.
13	MS. KING: JOAN SAMUELSON.
14	MS. SAMUELSON: NO.
15	MS. KING: JEFF SHEEHY.
16	MR. SHEEHY: YES.
17	MS. KING: ART TORRES.
18	CHAIRMAN TORRES: AYE. MOTION CARRIES.
19	ALL RIGHT. I THINK WE'VE REACHED THE END
20	OF OUR ROPE HERE OR RATHER THE END OF THE MEETING.
21	I JUST WANT TO TELL YOU THAT THIS HAS BEEN THE MOST
22	DELIGHTFUL COMMITTEE I HAVE EVER CHAIRED BECAUSE OF
23	THE THOUGHTFUL PRESENTATIONS AND COMMENTS BY BOTH
24	OUR BOARD MEMBERS AND THE PUBLIC THAT HAS
25	PARTICIPATED IN THIS HEARING. AND WE WILL CONTINUE
	86
	OU

```
1
      THIS DISCUSSION AUGUST 20TH. THE MEETING IS
 2
      ADJOURNED.
 3
                      (THE MEETING WAS THEN ADJOURNED AT
 4
      02:48 P.M.)
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                 87
```

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE LEGISLATIVE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON AUGUST 6, 2009, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100

88